# Overview

# Upgrading a Healthcare ETF Quant Strategy Project

## Executive Summary

James is preparing a 4-week quantitative strategy project focused on **healthcare sector ETFs** to bolster his candidacy for quant researcher roles in healthcare-focused hedge fund pods. His initial ideas – momentum rotation between biotech vs. broad healthcare ETFs, a pairs trade between pharma and hospital stocks, and a long/short factor bet on high-R\&D biotech vs. low-R\&D pharma – provide a starting point but require critical refinement. This report evaluates James’s skillset and gaps, surveys relevant literature on sector-based quant strategies (with emphasis on healthcare-specific insights), and proposes a roadmap of enhanced strategy ideas. We identify **4–5 advanced ETF-only strategies** that avoid common pitfalls (like overfitting or simplistic assumptions), emphasize risk-adjusted returns and factor awareness, and remain feasible within 4 weeks. From these, we select the top **1–2 strategy blueprints** tailored to James’s background (strong data science/biotech skills but limited finance experience) and to the expectations of healthcare hedge fund pods. Finally, we outline an implementation checklist to ensure the project demonstrates finance literacy, quantitative rigor, and solid research engineering practices.

**Key Recommendations:** James should leverage his proven coding and data-analysis abilities to implement strategies that showcase **investment hypothesis clarity, robust backtesting, and thorough risk analysis**. For example, an improved **biotech vs. healthcare momentum** strategy with volatility control or macro regime filters can highlight risk management and domain insight, while a **biotech–pharma factor long/short** strategy (market-neutral, with R\&D-driven rationale) can underscore his understanding of healthcare sector dynamics. Each chosen strategy must be evaluated with out-of-sample tests, factor exposure analysis, and stress tests to convince hedge fund interviewers that James can think and act like a practitioner. By following the plan in this report – including a literature-backed strategy design and a rigorous execution checklist – James will produce deliverables that demonstrate competence in portfolio construction, systematic strategy design, and critical evaluation of performance and risks.

## James’s Verified Skills vs. Gaps from CV

James’s CV confirms he has **strong technical and analytical skills** but also reveals gaps in finance-specific experience that this project should address:

* **Programming & Data Analysis:** James is proficient in Python, R, SQL, Bash, and workflow tools (Nextflow/Snakemake) with extensive experience building data pipelines[\[1\]](file://file-3p3YJtzbTrCpuyR3KaG14n#:~:text=Research%20Assistant%20at%20Sanjana%20Lab,Present)[\[2\]](file://file-3p3YJtzbTrCpuyR3KaG14n#:~:text=Developed%20single,high%20sensitivity%20in%20one%20experiment). He has applied machine learning (scikit-learn, PyTorch, TensorFlow) in scientific projects[\[3\]](file://file-3p3YJtzbTrCpuyR3KaG14n#:~:text=Computational%20Biology%3A%20Python%2C%20R%2C%20Bash%2C,MAGeCK%2FSCEPTRE%2FPertPy) and worked with high-performance computing and cloud resources (HPC, AWS)[\[4\]](file://file-3p3YJtzbTrCpuyR3KaG14n#:~:text=Computational%20Biology%3A%20Python%2C%20R%2C%20Bash%2C,MAGeCK%2FSCEPTRE%2FPertPy). These skills will transfer well to quantitative strategy development (data handling, backtesting code, etc.). *Gap:* While technically strong, he hasn’t yet applied these skills to financial time-series data or trading strategy code – the project will require him to learn financial libraries and data formats.

* **Quantitative Research Experience:** James’s background is in computational biology research. He has designed and implemented complex analyses (e.g. single-cell RNA-seq pipelines) and contributed to peer-reviewed scientific studies[\[5\]](file://file-3p3YJtzbTrCpuyR3KaG14n#:~:text=Peer). This shows he can formulate hypotheses and rigorously test them in a scientific context. *Gap:* He lacks direct exposure to financial research methods – e.g. he hasn’t done portfolio optimization, factor modeling, or performance attribution before. The project should bridge this by incorporating finance research techniques (e.g. Fama-French factor regressions, Sharpe/alpha calculations, out-of-sample validation) to demonstrate “finance literacy.”

* **Domain Knowledge – Healthcare:** James has deep knowledge in biotechnology and healthcare from his research roles. He understands drug development, biotech innovation cycles, and has published cancer research[\[6\]](file://file-3p3YJtzbTrCpuyR3KaG14n#:~:text=Lee%2C%20H.%20J.,Cancers). This domain expertise is a strength for a healthcare-focused fund. *Gap:* However, the CV shows **no direct finance or investment experience** – terms like portfolio, ETF, alpha, etc., are absent. To impress hedge funds, he must translate his domain knowledge into **investable insights**. The project should explicitly use healthcare industry context (e.g. R\&D intensity, regulatory impacts on subsectors) to shape strategy signals, showing he can connect science to market behavior.

* **Project/Software Engineering:** His projects (e.g. a drug repurposing tool and an LLM-based cell data annotator) indicate strong ability to develop and deploy analytical tools[\[7\]](file://file-3p3YJtzbTrCpuyR3KaG14n#:~:text=scPerturb,repurposing%20prediction%20for%20bench%20validation). He is comfortable with Git version control and reproducible research practices from academia. This suggests he can produce well-documented code and analyses. *Gap:* The challenge is to apply these engineering best practices in a **trading strategy context** – e.g. structuring backtest code that’s modular, logging results systematically, ensuring reproducibility of simulations. The project plan should include using these skills so that the final deliverables (code, report) meet professional standards.

**How the Project Will Address Gaps:** We will design the project so that James is forced to learn and demonstrate core quant finance concepts. For example, implementing a **sector rotation strategy** will require him to fetch historical price data and calculate returns, introducing him to financial data APIs. Evaluating strategy performance will push him to compute metrics like CAGR, volatility, Sharpe ratio, max drawdown, and maybe run a regression against market and factor returns – thereby showcasing understanding of performance evaluation beyond raw returns. To emphasize portfolio construction literacy, one of the advanced strategies will involve **market-neutral positioning** or **volatility position sizing**, illustrating risk management. By incorporating a section where James critiques his own strategy’s robustness (e.g. sensitivity to assumptions, potential biases, how it might fail in different regimes), he will demonstrate the critical thinking expected from a quant researcher.

## Literature Review: Sector Strategies & Healthcare Quant Insights

To upgrade James’s baseline ideas, we surveyed both academic research and practitioner insights on **quantitative sector rotation strategies**, **pairs trading**, and **healthcare-specific factors**. The literature underscores important considerations for designing a successful and novel ETF strategy:

* **Momentum and Sector Rotation:** Academic studies have examined momentum-based sector rotation, finding that simple approaches have become less effective over time. For instance, Belušká and Vojtko (2024) show that the historical alpha of basic sector momentum strategies has **diminished in recent years**, prompting the need for enhanced methods[\[8\]](https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4988543#:~:text=In%20this%20article%2C%20we%20explore,effective%20tool%20for%20systematic%20investors). In other words, chasing the top-performing sectors (e.g. biotech vs healthcare) with naïve momentum might no longer yield outperformance, possibly because many investors arbitraged it away or due to regime changes. They propose improvements to make sector momentum effective again[\[8\]](https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4988543#:~:text=In%20this%20article%2C%20we%20explore,effective%20tool%20for%20systematic%20investors) – these could include techniques like *volatility scaling, dynamic allocation, or incorporating additional signals*. In fact, broader momentum literature suggests that **volatility-adjusted momentum** can improve performance: volatility scaling of position sizes tends to boost risk-adjusted returns and reduce crashes[\[9\]](https://papers.ssrn.com/sol3/Delivery.cfm/SSRN_ID4689199_code73374.pdf?abstractid=4478316#:~:text=Strategy%20papers,the%20switching%20strategy%20has). This is highly relevant to James’s momentum rotation idea (XBI vs XLV) – simply rotating based on past returns may not impress a hedge fund, but an improved version that accounts for volatility or trend strength could add value. Notably, there is **scarce academic literature on sector ETFs** specifically[\[10\]](http://www.na-businesspress.com/JAF/JAF21-1/3_ColeFinal.pdf#:~:text=,the%20testing%20of%20these), implying this is a less explored niche where a well-executed project can stand out if it avoids the known pitfalls.

* **Pairs Trading and Mean Reversion:** Pairs trading (long one asset, short a related asset when their prices diverge) is a classic quant strategy, but results in recent decades have been mixed. Research indicates that while pairs trading showed strong profits historically (e.g. in the 1980s-90s), its edge has **waned and become less clear in modern markets[\[11\]](https://papers.ssrn.com/sol3/papers.cfm?abstract_id=2816288#:~:text=Is%20Daily%20Pairs%20Trading%20of,clear%20if%20it%20still)**. Applying pairs trading to ETFs (like a pharma ETF vs a hospitals/providers ETF) has the advantage of lower idiosyncratic risk (since each ETF is itself diversified), but also means opportunities might be smaller. Studies focusing on ETF pairs find that any mispricing between highly liquid ETFs tends to be corrected quickly, and transaction costs can eat into returns[\[11\]](https://papers.ssrn.com/sol3/papers.cfm?abstract_id=2816288#:~:text=Is%20Daily%20Pairs%20Trading%20of,clear%20if%20it%20still). However, a **cointegration approach** (ensuring a mean-reverting relationship) or focusing on structural breaks (e.g. regulatory events affecting pharma vs providers differently) might still yield a viable strategy. The literature implies that **if James pursues a pairs trade, he must carefully test stability** of the relationship and incorporate trading cost assumptions. A novel angle could be identifying a fundamental reason the pair should converge (for example, if hospitals and pharma revenues are both tied to healthcare spending trends, large divergences could correct). He should be aware that **data-snooping and overfitting** are risks in pairs selection; many candidate pairs should be tested out-of-sample to ensure the chosen one wasn’t cherry-picked. Overall, the takeaway is that a pairs strategy should be presented with caution and rigorous validation, otherwise it may seem too simplistic given that many are aware of its declining profitability.

* **Healthcare Sector Characteristics & Signals:** The healthcare sector is internally diverse, encompassing industries with very different behaviors. Practitioner analysis (e.g. from Saxo Bank) emphasizes that within healthcare, investors can target **“growth” segments like biotechnology or more “stable” segments like pharma or services**[\[12\]](https://www.home.saxo/content/articles/equities/healthcare-rotation--a-timely-diversification-opportunity-for-tech-heavy-portfolios-26112025#:~:text=Investor%20takeaway%3A%20Healthcare%20is%20diversified,risks%20alongside%20its%20potential%20benefits). Biotech firms are typically smaller, R\&D-intensive, and have volatile, binary outcomes (drug successes or failures), whereas big pharmaceutical companies and healthcare providers have steadier cash flows and often pay dividends[\[12\]](https://www.home.saxo/content/articles/equities/healthcare-rotation--a-timely-diversification-opportunity-for-tech-heavy-portfolios-26112025#:~:text=Investor%20takeaway%3A%20Healthcare%20is%20diversified,risks%20alongside%20its%20potential%20benefits)[\[13\]](https://www.home.saxo/content/articles/equities/healthcare-rotation--a-timely-diversification-opportunity-for-tech-heavy-portfolios-26112025#:~:text=Image%3A%2026_CHCA_Heanthcare%20performance%20gfc). Historically, biotech stocks carry higher risk: academic studies find **biotech firms have much higher R\&D intensity (\~38% of assets on average) and greater exposure to risk factors like market beta and size**[\[14\]](https://www.nber.org/papers/w13604#:~:text=The%20biotechnology%20industry%20has%20been,was%20only%20about%203%20percent)[\[15\]](https://www.nber.org/papers/w13604#:~:text=biotechnology%20firms%20to%20estimate%20several,be%20underestimated%20when%20a%20single). Indeed, Golec & Vernon (NBER 2007\) note that biotechnology is “by far the most research-intensive industry” and that biotech stock returns load significantly on the size and value/growth factors (meaning they behave like small, growth-oriented stocks)[\[14\]](https://www.nber.org/papers/w13604#:~:text=The%20biotechnology%20industry%20has%20been,was%20only%20about%203%20percent)[\[15\]](https://www.nber.org/papers/w13604#:~:text=biotechnology%20firms%20to%20estimate%20several,be%20underestimated%20when%20a%20single). This means a simple long-biotech/short-pharma bet might implicitly be capturing the size premium or growth vs. value factor rather than a unique “R\&D factor.” It’s crucial for James to acknowledge this in his factor idea: e.g. he could show via a regression that XBI (biotech ETF) has a high **SMB (small-cap) exposure** and relatively low value exposure, whereas a pharma ETF might tilt opposite. This insight from literature will let him argue whether an R\&D-heavy vs R\&D-light strategy is just a repackaged size trade or if there’s independent alpha (perhaps linked to **funding cycles** or drug innovation cycles). Notably, recent industry research found that **biotech companies earned higher excess returns than pharma in the mid-2010s when adjusting for R\&D as an investment** – one study showed that after capitalizing R\&D, pharma manufacturers’ returns were only modest (1.7% above cost of capital), whereas biotech manufacturers’ returns were far higher (\~9.6%)[\[16\]](https://link.springer.com/article/10.1007/s10754-020-09291-1#:~:text=of%20capital,the%20pharmaceutical%20supply%20chain%20are). This suggests that markets have rewarded the risk and innovation in biotech in certain periods, an argument James could use for a long-biotech/short-pharma trade (with the caveat that this may be cyclical). On the other hand, older analyses (circa 2009\) noted **biotech firms had more volatile profits and even suffered more negative stock returns than pharma over some horizons[\[17\]](https://pubmed.ncbi.nlm.nih.gov/19799470/#:~:text=,suffered%20more%20negative%20stock%20returns)**, highlighting that outcome depends on the timeframe and market environment. Overall, the literature teaches that **healthcare subsectors respond to different drivers**: e.g., biotech is very sensitive to **capital availability and risk appetite** (as one strategist put it, biotech is “particularly vulnerable to funding cycles”[\[13\]](https://www.home.saxo/content/articles/equities/healthcare-rotation--a-timely-diversification-opportunity-for-tech-heavy-portfolios-26112025#:~:text=Image%3A%2026_CHCA_Heanthcare%20performance%20gfc)), while pharma and providers are more defensive but face policy/regulatory risks (like drug price controls or Medicare reimbursement changes). Therefore, a successful strategy could be **regime-dependent** – e.g. during bull markets or low-rate environments, overweight high-R\&D biotech (growth tilt), but in recessions or high-rate regimes, shift to defensive healthcare (pharma, services). Incorporating such macro/regime awareness will significantly strengthen James’s project.

* **ETF-Based Strategy Methodology:** Using ETFs exclusively has pros and cons that the literature and industry experience shed light on. **Advantages:** ETFs are diversified, so idiosyncratic risks (e.g. a single drug trial failure) are smoothed out; this makes backtests more stable and avoids stock-specific data issues (no survivorship bias within an index ETF). Also, data for ETFs (prices, volumes) is easily accessible for free, and one avoids needing granular fundamental data for many individual companies. **Disadvantages:** Because ETFs are broad baskets, it may be harder to generate outsized alpha – much of the performance is driven by overall sector moves. Many ETF strategies (momentum, rotation, etc.) are well-known, so the **“edge” can get arbitraged** unless one adds a unique twist. Moreover, trading ETFs still requires consideration of costs (spreads can be small for big ETFs like XLV, but more specialized ones like XBI or a niche hospital ETF might have wider spreads). The **academic “seven sins” of backtesting** are fully applicable: even with ETFs, one must avoid look-ahead bias, data-snooping (overfitting signals on limited sector history), ignoring transaction costs, etc.[\[18\]](https://bookdown.org/palomar/portfoliooptimizationbook/8.2-seven-sins.html#:~:text=%2A%20Sin%20,Asymmetric%20pattern%20and%20shorting%20cost). For instance, **overfitting** is a major risk – it’s easy to test 100 variations of a rotation strategy on 15 years of ETF data and find one that would have made high returns in-sample, but such a backtest can be a statistical mirage. As one source highlights, many impressive backtests fail in live trading because they were effectively tuned to random noise in historical data[\[19\]](https://mathinvestor.org/2022/02/backtest-overfitting-and-the-post-hoc-probability-fallacy/#:~:text=By%20backtest%20overfitting%2C%20we%20mean,sample). James should explicitly show that he is aware of this by, say, using a separate validation period or limiting the complexity of his models. Additionally, **storytelling bias** – imposing a narrative on patterns after seeing results – should be avoided[\[20\]](https://bookdown.org/palomar/portfoliooptimizationbook/8.2-seven-sins.html#:~:text=8.2.3%20Sin%20); instead, start with a hypothesis grounded in finance or healthcare logic, then test it. By grounding strategy ideas in **the literature and domain insights above**, James can form credible hypotheses (e.g. “biotech should outperform pharma when real interest rates are falling, due to cheaper funding and higher risk appetite for R\&D”). These can then be tested objectively. Summarizing the lesson: **the project should combine proven quantitative techniques (momentum, mean-reversion, factor models) with healthcare-specific logic, implemented with rigorous backtesting standards.**

## Data Sources and Tools for an ETF Strategy

One constraint is that James must rely on **free or low-cost data sources**, which fortunately is quite feasible for an ETF-based project. Below we identify sources for the types of data he’ll need:

* **Price and Volume Data for ETFs:** James can obtain historical daily price data for ETFs (such as SPDR S\&P Biotech ETF XBI, SPDR Health Care Select Sector XLV, pharmaceutical ETFs, etc.) through free APIs. A popular choice is the Yahoo Finance API, which can be accessed in Python via the yfinance library – *“yfinance offers a Pythonic way to fetch financial & market data from Yahoo\! Finance”*[\[21\]](https://github.com/ranaroussi/yfinance#:~:text=Image%3A%20ranaroussi). Using yfinance, he can download decades of daily OHLCV data for any ETF without cost. For example, a simple Python script can pull adjusted close prices for XBI and XLV and save them to CSV for analysis. Yahoo’s data is generally reliable for backtesting (though he should be cautious about dividend adjustments and use total return when appropriate). Another free source is **Alpha Vantage**, which provides free daily time-series data for stocks and ETFs via API (with some rate limits) – *“the Alpha Vantage API offers finance data for stocks, ETFs… with a free API key and 500 daily calls limit”*[\[22\]](https://www.tha.de/en/library/Alpha-Vantage-API.html#:~:text=Alpha%20Vantage%20API%20,and%20500%20daily%20calls%20limit). James can easily get by with these options given a handful of tickers. Additionally, some community datasets on Kaggle or GitHub might have clean time-series for major ETFs, which could save time. Since only a few ETFs are in play, even manually downloading CSVs from Yahoo Finance’s site is an option.

* **Market and Factor Benchmarks:** To evaluate strategy performance properly, James will need benchmark indices (like the S\&P 500 or a healthcare sector index) and risk factor data. **Benchmark index:** He can use XLV (Health Care Select Sector SPDR) as the benchmark for healthcare sector performance, or SPY (SPDR S\&P 500 ETF) for a broad market benchmark. Their data is also available via Yahoo/Alpha Vantage. **Risk factor data:** For a rigorous analysis, obtaining Fama-French factor returns and other factors (e.g. momentum factor, SMB, HML, etc.) is important. The **Kenneth R. French Data Library** provides free monthly (and some daily) factor data and industry portfolio returns. For example, French’s website publishes the classic Fama-French 3-factor and 5-factor time series. Researchers often simply download these series as needed[\[23\]](https://www.sciencedirect.com/science/article/abs/pii/S1544612318301004#:~:text=We%20start%20with%20the%20well,6). James can pull the Fama-French factors (market excess return, SMB, HML, etc.) to run regressions and see if his strategies have alpha beyond known factors. This will show hedge funds he understands factor risk. Additionally, the data library has an “Industry Portfolios” dataset – one of which is a healthcare sector portfolio – which could be used for a longer-term perspective or validating ETF proxies.

* **Macro and Economic Data:** If incorporating **regime indicators** (e.g. interest rates, credit spreads, volatility index), James can use free sources like the St. Louis Fed’s **FRED** database. FRED provides a wide range of macro series (Treasury yields, corporate bond spreads, Fed funds rate, etc.) and has a free API[\[24\]](https://fred.stlouisfed.org/docs/api/fred/#:~:text=St,category%2C%20series%2C%20and%20other). For instance, he could fetch the 10-year Treasury yield or the Moody’s BAA corporate bond yield to proxy funding conditions for biotech. The CBOE Volatility Index (VIX) levels can be downloaded from Yahoo Finance as well (ticker ^VIX). Economic series (like PMI, GDP growth, etc.) are also on FRED if needed for a regime filter. All these are accessible without cost; he just needs to be mindful of aligning frequencies (most will be monthly or daily).

* **ETF Constituent or Fundamental Data:** Since James is restricting to ETFs (no single-stock analysis), he likely won’t dive deeply into individual company fundamentals. However, understanding the compositions could help (e.g. what stocks dominate XLV vs XBI). ETF providers (State Street, iShares, etc.) publish factsheets listing top holdings, sector breakdowns, and sometimes aggregated fundamentals (like average P/E, average R\&D expense of the holdings, etc.). These can often be scraped or manually noted from provider websites or free sites like ETFdb or Yahoo (which sometimes lists P/E, dividend yield of an ETF). If James pursues the R\&D factor idea rigorously, he might try to approximate “R\&D intensity” of an ETF’s portfolio using external data (for example, taking weighted average R\&D-to-sales of top holdings using financial statements). However, given the 4-week limit and free data constraint, it’s acceptable if he proxies this concept with the ETFs themselves (assuming XBI is “R\&D-heavy biotech” and, say, an ETF like XPH or IHE for pharmaceuticals represents “lower R\&D pharma”). He should note the limitation that this is a coarse approach. If needed, some fundamental data can be obtained via **Alpha Vantage** (they have quarterly financials for many stocks via API) or Yahoo (via yfinance which can sometimes retrieve ratios for tickers). But this could be advanced and time-consuming, so it might be a stretch goal.

* **Tools and Libraries:** Apart from data sources, the tech stack will be Python-centric. Key libraries likely include: pandas and numpy for data manipulation, matplotlib/seaborn for plotting equity curves and drawdowns, statsmodels or scipy for statistical tests (e.g. checking cointegration or running regressions), and possibly backtrader or a simple custom loop for backtesting logic. Given James’s coding skills, he could write his own backtest functions to learn the mechanics, but using a lightweight framework or library functions (like pandas.DataFrame.pct\_change for returns, rolling window calculations for momentum, etc.) will save time. Git for version control and Jupyter notebooks for iterative analysis would align with his past workflow.

In summary, **data availability will not be a bottleneck** for this project – free resources cover all needs (price histories, factor data, macro data). The focus will be on *using* this data effectively and correctly. James must also document data sources in his report to show he’s mindful of data reliability (e.g. acknowledging if there are any missing days or corporate actions in the ETF price data and how he handled them). Ensuring the data is clean (adjusted for splits/dividends) and timestamps are aligned (avoiding look-ahead, using appropriate train/test splits) will be part of the rigorous approach.

## Evaluation of Baseline Strategy Ideas

Before devising new strategies, we critically evaluate the **feasibility, novelty, and robustness** of James’s baseline ideas. Each idea is scored qualitatively on these dimensions to identify where improvements are needed:

**1\. Momentum Rotation: Biotech vs. Broad Healthcare (XBI vs XLV)** – *Idea:* Alternate between a biotech ETF (e.g. XBI) and a broad healthcare ETF (XLV) based on momentum (for example, invest in whichever had higher recent returns, or use a trend signal to overweight one vs the other).

* **Feasibility:** *Very High.* This strategy is straightforward to implement with readily available price data. Only two ETFs are involved, and computing momentum (say 3-month or 6-month trailing return) is simple. Transaction frequency can be low (monthly or quarterly switches), so data frequency and trading costs are manageable.

* **Novelty:** *Low.* Sector rotation based on momentum is a well-known idea; many funds and publications have explored it. Switching between two specific sector ETFs is a narrow case of a common momentum/trend following strategy. Without enhancements, it may appear too simplistic or *“off-the-shelf.”* Indeed, the concept of rotating into biotech when it has relative strength could be seen as an obvious play that many investors try (diminishing its edge). Literature suggests the raw approach likely has little alpha left[\[8\]](https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4988543#:~:text=In%20this%20article%2C%20we%20explore,effective%20tool%20for%20systematic%20investors).

* **Robustness & Risks:** *Moderate.* Momentum strategies can suffer during regime changes or whipsaw periods. With only two assets, the strategy’s performance might hinge on a few correct switches. There’s risk of **overfitting the look-back period** or threshold – e.g. a 3-month vs 6-month momentum might flip the historical results, and choosing one could be just cherry-picking. Also, **momentum in sectors has seen attenuated performance in recent years[\[8\]](https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4988543#:~:text=In%20this%20article%2C%20we%20explore,effective%20tool%20for%20systematic%20investors)**, possibly requiring modifications like volatility scaling or combining it with a trend filter (to avoid false signals). On the positive side, momentum is a persistent anomaly in many markets, so with proper tuning (and acknowledging the diminishing returns), it could still add value. **Score:** *This idea scores high on ease but low on distinctiveness.* It needs additional layers (e.g. volatility-targeting to improve Sharpe, or a rule to go to cash if both ETFs are in downtrend, etc.) to be compelling. We will likely incorporate this idea into a more advanced “tactical rotation with risk management” strategy.

**2\. Pairs Trading: Pharma vs. Hospitals/Providers** – *Idea:* Go long one subsector (e.g. pharmaceutical companies ETF) and short another (e.g. healthcare providers/hospitals ETF) to exploit relative mispricing. The hypothesis might be that these two subsectors should move together to some extent (both part of healthcare), so deviations in their relative performance mean-revert.

* **Feasibility:** *Medium.* This requires identifying appropriate ETF proxies – for pharma, there are ETFs like SPDR S\&P Pharmaceuticals (XPH) or iShares U.S. Pharmaceuticals (IHE), and for healthcare providers/hospitals, an ETF like iShares U.S. Healthcare Providers (IHF) could serve (IHF holds insurers, hospital companies, etc.). Data for these is available, but liquidity and history vary (IHF inception was 2006, XPH 2006 as well, so \~18+ years of data – decent). Implementing a pairs trade means deciding on entry/exit conditions (e.g. z-score of price ratio). It’s a bit more involved than the momentum switch, but still quite doable in Python. He might need to test for cointegration to justify that a stable relationship exists.

* **Novelty:** *Moderate.* While pairs trading in general is old, applying it to these specific healthcare subsectors is somewhat niche. It’s not a very commonly publicized pair (unlike, say, Coke vs Pepsi or stock vs stock pairs). There could be a fundamental rationale: pharma and providers are opposite sides of healthcare costs (if drug prices rise, maybe insurers suffer, etc.), but they also both depend on overall healthcare demand. The novelty could be in the domain explanation (e.g. “demographics drive both pharma and hospitals similarly, so their fortunes are linked”). However, many hedge funds are likely familiar with sector pairs trades, so it won’t be groundbreaking unless he adds a twist (like dynamic hedging or integrating a catalyst signal).

* **Robustness & Risks:** *Low to Moderate.* The biggest concern is whether the pair truly has a mean-reverting relationship. Pharma vs providers might trend apart for long periods due to structural changes (for example, political developments could favor one side for years). Unlike classic pairs of two very similar companies, these are different industries – one might get a multi-year boost (e.g. insurers benefitting from policy change) while pharma lags, and they might **not revert in a timely way**, causing sustained losses for a simple mean-reversion strategy. Academic evidence suggests generic pairs strategies have struggled, and any single pair is risky[\[11\]](https://papers.ssrn.com/sol3/papers.cfm?abstract_id=2816288#:~:text=Is%20Daily%20Pairs%20Trading%20of,clear%20if%20it%20still). Additionally, a long/short strategy must consider **borrowing costs** and **transaction costs** (shorting an ETF like IHF should be feasible but might incur some cost; turnover could be an issue if the strategy trades frequently on volatility). If pursued, James should mitigate these by (a) testing cointegration and only trading when statistically significant deviations occur, (b) including cost assumptions (perhaps \~$0.01 bid-ask and a short borrow rate), and (c) monitoring **divergence risk** (maybe a stop-loss if the spread keeps widening beyond a threshold). **Score:** *This idea has some domain appeal but is risky.* It would score better if combined with a clear fundamental justification and safeguards. We might roll this concept into a broader **statistical arbitrage** idea or use it as one example of a relative trade within a larger framework (e.g. trading a basket of healthcare pairs to diversify risk).

**3\. Factor Long/Short: R\&D-Heavy Biotech vs. Low-R\&D Pharma** – *Idea:* Construct a long/short portfolio that is long “high R\&D intensity” biotech companies and short “low R\&D intensity” pharma companies, expecting the former to outperform or as a way to isolate an “innovation” factor premium. Since James is using ETFs only, this likely means going long a biotech-focused ETF (XBI or iShares Nasdaq Biotech IBB) and short a pharma-focused ETF (XPH/IHE), under the assumption that biotech’s heavy R\&D spending leads to higher growth or that pharma’s lower R\&D (and reliance on marketing or acquisitions) makes it a stable but lower-return segment.

* **Feasibility:** *Medium.* As noted, directly quantifying R\&D intensity via free data is challenging at the ETF level. However, using **XBI vs XPH** as proxies is plausible – historically, biotech indices have much higher average R\&D-to-sales than big pharma. Another approach could be splitting a broad healthcare ETF by company type, but that’s complicated. Sticking to ETFs, implementation is straightforward (similar to a pairs trade structure but with a specific thesis). Data is available for both XBI and XPH since mid-2000s. The strategy would be essentially static long/short (unless he adds timing). Feasibility is fine, but he must be careful to justify that these two ETFs indeed represent the intended concept.

* **Novelty:** *High (Conceptually).* This idea leverages James’s **domain knowledge** in a creative way. It’s not a standard factor that every quant talks about – it’s akin to an “innovation factor” within healthcare. Hedge fund managers focused on healthcare might find this intriguing, as it shows James thinking about how fundamental differences (R\&D investment behavior) translate to stock performance. It differentiates him from someone who only knows technical signals. That said, it will be novel only if he can articulate it well and perhaps show evidence (e.g. “over the last 10 years, an R\&D-heavy index outperformed an R\&D-light index by X% annually”). If literature or data doesn’t support outperformance, it could still be interesting as a **market-neutral hedge** (biotech vs pharma spread) to analyze its properties (volatility, correlation with market).

* **Robustness & Considerations:** *Uncertain.* A key risk is that this long/short essentially replicates known risk factors: biotech tends to be smaller cap, more growth-oriented, and more volatile, whereas big pharma are often larger, value/dividend-paying companies. So the performance of this trade may simply reflect the **small-minus-big (SMB) factor or growth-minus-value**. Indeed, NBER research indicates biotech carries a higher cost of capital (16%+ historically) and loads on size and possibly momentum factors[\[25\]](https://www.nber.org/papers/w13604#:~:text=the%20CAPM%20does%20not%20reflect,factor%20model)[\[26\]](https://www.nber.org/papers/w13604#:~:text=In%20the%20current%20study%20we,prices%20and%20returns%2C%20and%20R%26D). If James finds that the long/short correlates strongly with, say, the Russell 2000 vs S\&P 500, then the “R\&D factor” might not be truly independent. He should test the long/short portfolio’s beta to the market and other factors – it might have a significant market beta (biotech often moves more with market in risk-on periods). To be robust, he might consider **beta-neutralizing** the trade (adjust weights so the portfolio has \~0 net market exposure) and/or **factor-neutralizing** (though neutralizing SMB might be hard with just two ETFs). Another issue: the viability of this strategy likely fluctuates with regimes – e.g., in periods of cheap money and high risk appetite, biotech outruns pharma (as seen in 2020-2021), but in risk-off periods biotech crashes (as in 2022\) and pharma holds up. This suggests adding a timing element (don’t always hold the long/short, but tilt it based on macro). Without timing, this could suffer long droughts. **Score:** *This idea is compelling as a talking point and can be made rigorous by connecting to factors.* We will carry this forward as one of the promising strategies, likely augmenting it with a regime filter (to decide when to bet on biotech vs when to reduce exposure). It will let James showcase both **healthcare insight** (R\&D importance) and **quant rigor** (risk-neutral positioning, factor analysis).

To summarize the baseline evaluation, we present a comparison:

| Baseline Idea | Feasibility (data & coding) | Novelty (originality) | Robustness (likely OOS performance) | Notes for Improvement |
| :---- | :---- | :---- | :---- | :---- |
| **Biotech vs Healthcare Momentum** | **High** – trivial to get prices & implement rules. | **Low** – well-known strategy, needs twist. | **Moderate** – momentum effect exists but much weaker now[\[8\]](https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4988543#:~:text=In%20this%20article%2C%20we%20explore,effective%20tool%20for%20systematic%20investors). Single parameter can overfit; risk of whipsaw. | Add volatility targeting or multiple-sector universe to enhance. Consider “go to cash” rule to avoid bad regimes. |
| **Pharma vs Providers Pair Trade** | **Medium** – data available, must ensure cointegration. | **Medium** – sector pair idea is niche but pairs trading itself is common. | **Low** – pairs profits mostly arbitraged out[\[11\]](https://papers.ssrn.com/sol3/papers.cfm?abstract_id=2816288#:~:text=Is%20Daily%20Pairs%20Trading%20of,clear%20if%20it%20still); this particular pair may drift on fundamentals. | Use cointegration test; possibly incorporate a catalyst (e.g. trade only around earnings/policy events). Strict stop-loss to control divergence. |
| **R\&D Factor Long/Short (Bio – Pharma)** | **Medium** – can proxy via XBI vs XPH ETFs; simple long/short code. | **High** – leverages domain concept; not a standard factor everyone uses. | **Uncertain** – could just mirror small-cap vs large-cap factor[\[15\]](https://www.nber.org/papers/w13604#:~:text=biotechnology%20firms%20to%20estimate%20several,be%20underestimated%20when%20a%20single); performance likely regime-dependent. | Perform factor regression to isolate true alpha. Possibly apply a macro filter (e.g. only long biotech vs pharma when interest rates falling or when biotech momentum is positive). |

This evaluation shows that **each idea has merit but also flaws**. The momentum and pairs strategies need modernization to be attractive, and the R\&D factor strategy needs careful validation and potentially a timing element. These findings will inform the next section, where we design a set of improved strategy frameworks that build on these ideas.

## Advanced ETF-Only Strategy Proposals

Drawing on the gaps identified and the literature insights, we propose **five advanced strategy frameworks** that James can consider. Each is designed to **avoid common backtest weaknesses** (overfitting, lack of risk control, etc.) and emphasize aspects that hedge fund interviewers value (risk-adjusted returns, factor awareness, adaptability to regimes). Importantly, all are implementable with ETF data and within a 4-week research window. The strategies range from momentum-based to market-neutral, combining technical and fundamental/macro signals:

**Strategy 1: Volatility-Managed Sector Momentum** – *Enhancing the baseline momentum rotation.* In this strategy, James would rotate between healthcare subsector ETFs based on momentum, but with a volatility targeting overlay to improve Sharpe and reduce drawdowns. For example, he could expand beyond just XBI and XLV to include 3-4 healthcare ETFs (biotech, pharma, medical devices, healthcare services) and each month pick the one or two with the strongest 6-month momentum to overweight. Crucially, positions would be scaled by inverse volatility: allocate more to lower-volatility sectors and less to higher-volatility ones so that each contributes more equally to risk. This addresses the issue that biotech is far more volatile than, say, big pharma – without vol scaling, a momentum strategy might suffer big swings when it tilts into biotech. Research supports this approach: *“volatility scaling improves the performance of momentum strategies”* by adjusting for risk[\[9\]](https://papers.ssrn.com/sol3/Delivery.cfm/SSRN_ID4689199_code73374.pdf?abstractid=4478316#:~:text=Strategy%20papers,the%20switching%20strategy%20has). Additionally, James can impose a **volatility cap or target** on the portfolio overall (e.g. target 10% annualized volatility by adjusting position size, or move partially to cash if all sectors are turbulent). This strategy would emphasize **risk-adjusted returns** – perhaps optimize for maximum Sharpe rather than raw returns. It also counters momentum’s Achilles heel: crashes following high-vol periods. Another enhancement: include a **“cash filter”** – if all healthcare ETFs have negative momentum (meaning the whole sector is in a downturn), the strategy can move to cash or a defensive asset (perhaps a Treasury bond ETF) instead of staying long a losing sector. This avoids being fully invested during sector-wide bear markets (e.g. 2022 when both biotech and pharma fell). The deliverable from this strategy would be a *tactical allocation model* that switches between healthcare sub-sectors (and possibly cash) in a way that is **trend-following but volatility-aware**. James can then compare its performance to a naive momentum approach to demonstrate the improvement (e.g. higher Sharpe, lower max drawdown, less frenetic trading). This proposal directly shows that he understands **risk management** (vol targeting is a technique many quant funds use) and can still harness momentum in a refined way.

**Strategy 2: Macro Regime Rotation (Risk-On vs Risk-Off in Healthcare)** – This strategy uses **macro indicators to toggle between offensive and defensive positions within healthcare**, aligning with James’s understanding of how biotech vs pharma perform under different conditions. The core idea: define regimes such as “Risk-On” (e.g. low credit spreads, declining interest rates, bullish equity trend) vs “Risk-Off” (e.g. rising yields, widening credit spreads, high volatility). In risk-on regimes, the strategy tilts toward high-beta, high-R\&D sectors (biotech, maybe small-cap healthcare ETF); in risk-off regimes, tilt toward defensive healthcare (pharma, healthcare providers, or even hold a healthcare bond proxy if available). Concretely, James could create a simple regime classifier: for instance, use the **10-year Treasury yield** and **VIX** level – if yields have fallen by X basis points over last 6 months and VIX is below Y, call it a “easy money & calm” environment (risk-on); if yields rising and VIX \> threshold, that’s risk-off. Another approach is using the **credit spread** (BBB corporate yield minus Treasury) as an indicator of funding stress – biotech heavily relies on capital markets for funding R\&D, so when spreads blow out, biotech underperforms. Literature and industry commentary back this: biotech thrives when capital is cheap and abundant[\[13\]](https://www.home.saxo/content/articles/equities/healthcare-rotation--a-timely-diversification-opportunity-for-tech-heavy-portfolios-26112025#:~:text=Image%3A%2026_CHCA_Heanthcare%20performance%20gfc). With a regime signal in hand, the strategy can do something like: *Risk-on \-\> 100% XBI (biotech ETF); Risk-off \-\> 100% XLV or XPH (pharma ETF), or a 50/50 to reduce risk.* To add nuance, he could still incorporate momentum within each regime (e.g. only shift after confirmation by price trend). This strategy showcases **regime dependence**, a sophisticated concept that many funds employ (different playbooks for bull vs bear markets). It leverages macro data (so James shows he can integrate economics with finance). Implementation is not too complex (he can get yield and VIX data free, and it’s mostly a few if-else rules around his portfolio allocation). The key will be demonstrating that this improves outcomes: e.g. show that historically, a regime-aware strategy had better drawdown control than a static allocation. It will also naturally highlight factor exposure differences: in risk-on phases, the portfolio will have more **SMB and momentum factor exposure** (because biotech often rallies then), whereas in risk-off it will carry a more **defensive, low-beta profile**. This is a great opportunity for James to discuss how factor exposures shift – something a hedge fund would find impressive in a candidate. The deliverable can include an analysis of, say, the 2020-2021 boom (risk-on, biotech surged) versus 2022 crash (risk-off, strategy would have rotated to pharma or cash, avoiding the worst). By correctly identifying these regimes (even with a simple rule), the strategy would have navigated the volatility far better than a naive constant exposure.

**Strategy 3: Multi-Factor Composite Signal (Quality, Value & Momentum in Healthcare ETFs)** – Instead of relying on any single signal (which might be fragile), this strategy would combine **multiple factors** at the ETF level to rank or score healthcare ETFs. For example, James can create a composite score for each ETF using: 1\) **Momentum** (relative strength over 6-12 months), 2\) **Value** (e.g. dividend yield or earnings yield of the ETF’s holdings), and 3\) **Quality** or **Low Volatility** (e.g. volatility of returns or perhaps a fundamental proxy like return-on-equity of holdings if data allows). The idea is to pick the ETF that has a good blend of positive momentum, reasonable valuation, and lower risk. In practice, this might be as simple as z-scoring each metric and summing up, or a weighted formula. Academic research on factor investing suggests combining factors can produce more stable performance – when one factor is out of favor, another might excel. For instance, momentum might tell you to buy biotech now, but valuation might warn that biotech is extremely pricey relative to pharma; a combined approach might moderate the position size or choose a mix rather than all-in. James can draw on known factor definitions (Fama-French value, quality metrics from literature like debt levels or profitability, etc.) at a sector level. Some data will be needed: ETF fact sheets or a site like ETFdb might give P/E ratios for each ETF, and volatility can be computed from price history. This strategy directly shows **knowledge of factor investing** – a buzzword in quant roles. It also demonstrates avoidance of a single-point failure: instead of betting only on momentum (which might crash if momentum regime flips), it builds a more robust stock selection (or ETF selection) model. Implementation in 4 weeks is feasible: with a handful of ETFs and a few metrics, it’s mostly data gathering and a loop to compute scores each period. However, James should be careful to **prevent overfitting** here – with potentially many parameters (weights of each factor, look-back windows, etc.), one could data-mine the best combination. He should pick sensible defaults from literature (e.g. momentum 12-month, value via dividend yield, equal weights) and then **validate out-of-sample**. He can even do an out-of-sample test by splitting history (train on 2007-2016, test on 2017-2023, for example) to show the composite works in test data. This process itself will impress the audience, as it mirrors what quants do in practice to avoid p-hacking. The final product might be a **ranking system** that each month ranks, say, XBI, XLV, XPH, IHF, etc., and allocates more to those with highest composite rank (long the top one or two, possibly short the bottom one or underweight it). This is essentially a **sector allocation model** with a multifactor alpha model – exactly the kind of thing many quant funds do (though typically across all sectors, here it’s within healthcare). It will let James talk about how certain factors behave in healthcare (e.g. “pharma ETFs usually have higher dividend yield (value) but often low momentum; biotech is opposite – high momentum in bull runs but very poor value metrics”). This nuanced understanding will stand out.

**Strategy 4: Cointegration-Based Statistical Arbitrage (Basket Trading)** – Building on the pairs trading idea, this strategy takes a more systematic stat-arb approach. Instead of just one pair, James could identify a **combination of healthcare ETFs that forms a stable spread** and trade that spread. For example, use a linear combination of ETFs that cancels out common trends: perhaps XLV (broad healthcare) can be modeled as some weight of Pharma ETF \+ some weight of Providers ETF \+ some weight of Biotech ETF. If he finds a linear combination like XLV – 0.5\*XPH – 0.5\*IHF that is mean-reverting (just a hypothetical), he can monitor its deviations. When the spread is far from its mean (e.g. XLV is too high relative to XPH and IHF), short XLV and go long the others, expecting convergence. Conversely, if XLV is too low, do the opposite. This is essentially a **sector mean-reversion trade** that exploits temporary divergences between sub-sector performance and the overall sector. It’s more advanced because it requires statistical analysis (cointegration tests, estimation of hedge ratios) and simultaneous trading of 3+ instruments. However, this might be doable in 4 weeks on a small scale (just a few ETFs). Another example: cointegration between **IBB (another biotech index) and XBI** – if both track similar indices, any divergence might be arbitraged (though they are quite similar, so less interesting). Or between **healthcare sector ETFs from different providers** (like XLV vs VHT (Vanguard Health) vs IYH (iShares US Health)) – they all track similar holdings, so a pairs trade between them could exploit small pricing differences or timing differences. That is a more high-frequency idea though, likely too fine for James’s scope. Sticking to broader dislocations between industries is more meaningful. The novelty here is that he’s not just guessing pairs, but using a **data-driven approach to find stationary relationships**. It addresses the earlier concern that a random pair might drift apart – by requiring cointegration, he ensures there’s a statistical equilibrium. If successful, this strategy would show James’s capability in **time-series analysis** and understanding of market-neutral trading. It also inherently handles market risk (if he longs one subset of healthcare and shorts another, the portfolio might be hedged against overall market moves to some extent, focusing on relative value). The complexity is higher – he’ll need to explain concepts like cointegration in simple terms (e.g. “these assets share common factors; I found a combination that removes the common trend, leaving a mean-reverting residual”). He also needs to be wary of overfitting – cointegration can appear by chance in short samples. A robust check is to use an in-sample period to fit the combination and then test forward if it held (similar to pairs trading methodology in academic papers). Given the limited time, James might demonstrate this on one compelling example rather than a whole optimization. Even so, including this as one of the strategy proposals shows he’s thinking beyond plain-vanilla ideas and is aware of **stat arb techniques** used by quant funds. In implementation, he’d use linear regression to find hedge ratios and perhaps the Engle-Granger two-step method or Johansen test for cointegration. The output could be a chart of the spread over time and trades indicated, with metrics like annual return, vol, Sharpe, etc. Because this is technical, he should pair it with a **fundamental story** for credibility: e.g. “Interestingly, my analysis found that a combo of pharma and providers vs biotech was mean-reverting – likely because pharma and providers are both cash-flow stable businesses whereas biotech’s swings eventually correct relative to them.” Such a narrative ties the quant result to economic reality.

**Strategy 5: Factor-Neutral Long/Short “R\&D Beta” Strategy** – This is a refined version of the R\&D-heavy vs R\&D-light idea, structured to isolate that factor while neutralizing others. If James wants to really impress, he could construct a **market-neutral long/short portfolio** within healthcare that aims to capture the “innovation/R\&D premium.” For example, long XBI (biotech) and short XLV (broad healthcare) in such proportion that the **overall portfolio has zero market beta** (or zero sector beta). He could do this by regressing XBI vs XLV or simply by noting that XLV contains biotech as a subset: if biotech is \~20% of XLV, then long 1 unit XBI, short 0.2 units XLV would net out biotech market exposure and isolate the extra part of biotech. The result is a long/short spread that’s roughly uncorrelated with the market’s directional moves. This isolates what one might call **“biotech excess return”**. He can then analyze whether this spread has positive expectation (does biotech outperform the rest of healthcare on a risk-adjusted basis or vice versa?). If yes, that’s the R\&D alpha. If not, perhaps it’s zero or negative (maybe biotech underperforms on average, except in certain cycles). Either result is interesting: he can show he thought to check it. To avoid being static, he could introduce a timing element here too: e.g. only deploy this long/short when certain conditions are met (similar to Strategy 2’s macro idea or Strategy 1’s momentum idea). One concrete framing: **“Trend \+ Hedge”** – go long XBI and short XLV (market-neutral) only when biotech momentum is positive and XLV momentum is negative, for instance (meaning biotech is trending up relative to broad health). This ensures he’s not always in the trade, only when it’s potentially favorable. Alternatively, **volatility control** on the spread – if the spread volatility spikes (meaning biotech is extremely volatile relative to XLV), maybe step aside (because that could mean something fundamental changed). The factor-neutral long/short showcases **factor investing concepts**: by neutralizing market beta (and maybe size factor if short XLV which is large-cap heavy), he’s attempting to isolate a specific factor. He can then evaluate its returns and risks. Perhaps he finds that the R\&D factor has a large upside in bull markets but crashes in bear markets (which is plausible). He could then propose a risk mitigation (like a stop-loss or a macro overlay as earlier). This strategy is essentially a special case of a long/short equity factor strategy and will resonate well with quant interviewers who often think in terms of *“betas”* and *“alphas.”* James can say, “I constructed a portfolio that’s beta-neutral to the healthcare sector to purely capture the R\&D-driven growth factor; I then analyzed its performance and found X, and I applied Y to improve its Sharpe.” This narrative would demonstrate a high level of analytical maturity for a candidate coming from a non-finance background.

These five strategies cover a spectrum of approaches (trend-following, factor investing, stat arb, macro overlay) and each is grounded in either a known quant concept or a healthcare-specific insight (or both). All are **modular and testable** within a few weeks, especially since the universe is small (handful of ETFs). James doesn’t need to implement all of them – the goal is to have a **rich menu of options** and then pick the best one or two to fully develop (which is the next step).

## Selecting the Best 1–2 Project Blueprints

From the above proposals, we now identify the top candidates that align best with James’s strengths and the expectations of healthcare-focused hedge fund pods. We choose two strategy blueprints to flesh out in detail:

### **Blueprint A: Regime-Switching Biotech vs Pharma Strategy**

**Strategy Outline:** This is a **regime-dependent rotation** between biotech and pharma sub-sectors, combining elements of Strategy 2 (macro regime filters) and Strategy 5 (R\&D factor long/short) from the proposals. The core idea is to **go long the biotech ETF and short the pharma ETF during “risk-on” periods** (when biotech is likely to outperform), and do the opposite or remain market-neutral during “risk-off” periods (when pharma’s stability is favored). Essentially, the strategy times the “biotech minus pharma” trade based on macro and market indicators.

* **Rationale:** Biotech (R\&D-heavy, high-growth) tends to outperform pharma (lower R\&D, value/defensive) when investors have an appetite for risk and when capital is cheap (e.g. low interest rates, high liquidity), because funding is plentiful for speculative R\&D endeavors and valuations expand. In contrast, in downturns or when interest rates rise, biotech underperforms as funding dries up and investors seek the relative safety of big pharma’s earnings and dividends. This rationale is supported by industry observations (*“biotech is particularly vulnerable to funding cycles”*[\[13\]](https://www.home.saxo/content/articles/equities/healthcare-rotation--a-timely-diversification-opportunity-for-tech-heavy-portfolios-26112025#:~:text=Image%3A%2026_CHCA_Heanthcare%20performance%20gfc)) and academic insight that biotech carries higher systematic risk[\[26\]](https://www.nber.org/papers/w13604#:~:text=In%20the%20current%20study%20we,prices%20and%20returns%2C%20and%20R%26D). By explicitly conditioning on regimes, James shows he’s leveraging his domain knowledge of how **macro conditions affect healthcare innovation**.

* **Regime Indicators:** To implement this, James will define specific, quantitative triggers for regimes. For example, he might use:

* **Interest rate trend** – If the 10-year Treasury yield has fallen by say \>50 bps over the last 6 months, that’s a proxy for easing financial conditions (risk-on for biotech). Conversely, a sharp rise in yields indicates tightening (risk-off).

* **Equity market momentum or volatility** – If the S\&P 500 (or Nasdaq) is in an uptrend (above its 200-day moving average) and the VIX is low (\< a threshold), risk sentiment is positive. If the market is below the MA or VIX is elevated, sentiment is cautious.

* **Credit spreads** – Using FRED data for something like BAA corporate bond spreads: low or narrowing spreads \= risk-on, widening spreads \= risk-off.  
  James can combine a couple of these into a simple rule (e.g. two out of three indicators signaling risk-on means go long biotech vs pharma; if majority risk-off signals, then avoid that trade or even reverse it).

* **Positioning:** In a pure implementation, risk-on regime \=\> **Long XBI, Short XPH** (or long biotech index, short pharma index). To make it more beta-neutral, he could calibrate the size of each leg such that the portfolio has near zero net exposure to the broader market or sector. For instance, if pharma ETF has a beta of 0.8 to SPY and biotech has 1.2, he might long $1 of XBI and short $1.5 of XPH to roughly cancel out market beta (these numbers could be estimated via regression). However, that level of precision may not be necessary for the project; a simpler 100% long XBI vs 100% short XPH might suffice to convey the idea (he can note the residual beta and maybe show it’s not too large, or easily hedged with a small SPY short if needed). In risk-off regimes, the safest approach could be to **go to market-neutral or cash** – perhaps hold an equal long and short (effectively hedged) or even invert (long pharma, short biotech) if the data supports that pharma strongly outperforms in those times. The inversion (long pharma in risk-off) might add returns but also could reduce the strategy’s market neutrality (pharma is still somewhat correlated with the market). Alternatively, risk-off regime could simply mean **stay out of the trade** (both legs in cash), thereby preserving capital and reducing volatility. James can test both approaches.

* **Performance Metrics & Expectations:** This strategy will likely produce a **high Sharpe, low beta** return stream if done correctly. Its goal is relative value gains, not big directional profits. We expect it to have modest returns (since on average, over long periods, pharma and biotech both tend to rise, so going long one vs short the other yields a lower return than being long both). However, the benefit is in **alpha generation** uncorrelated to the market. For example, in a period like 2019-2020 (low rates, bullish): the strategy would have been mostly long biotech/short pharma, capturing biotech’s outperformance (XBI surged far more than big pharma did). In 2022 (rates up, bearish): the model would flip or go neutral, avoiding the huge drawdown in biotech (XBI was down \~-25% in 2022 while some pharma stocks were up, e.g. Merck, or flat). This would result in a positive gain on the spread (since pharma outperformed biotech by a big margin that year). By demonstrating such outcomes, James can argue the strategy provides **downside protection** in tough markets and participation in up markets – a holy grail for investors. He will calculate metrics like annualized return, volatility, Sharpe ratio, maximum drawdown of the strategy vs. say a static 50/50 biotech-pharma or vs. the S\&P 500\. He should also compute the **information ratio** (alpha divided by residual risk) to show it delivers alpha relative to a healthcare benchmark.

* **Risks and Robustness Checks:** James must address what could go wrong. For example, the regime signals might sometimes whipsaw (regimes aren’t binary in reality). If the strategy switches too late or too early, it could suffer. He can mitigate this by not over-trading: e.g. require a regime to hold for at least 3 months before acting, to avoid noise. Another risk: an unforeseen event specific to one side (e.g. a major biotech crash on a drug failure in a large index component, or a pharma meltdown due to a scandal) that is unrelated to macro regime. Since this is a diversified ETF, that risk is smaller, but still there. He can discuss including a stop-loss on the spread: if the long/short loses more than, say, 5% in a short time, step aside (maybe the regime model missed something). **Out-of-sample testing** is crucial: he can calibrate his regime threshold on older data (say 2005–2015), then test 2016–2023 as out-of-sample to see if the performance holds. Also, he should test sensitivity: if he tweaks the interest rate threshold or the moving average length, does the strategy fundamentally still work? If a strategy is extremely sensitive to small parameter changes, that’s a sign of overfitting. He should report that analysis.

* **Why it Fits James & the Audience:** This blueprint leverages James’s **healthcare domain knowledge** (understanding biotech vs pharma drivers) and shows he learned to integrate **macro analysis and quant signals**. Hedge fund interviewers will appreciate that he’s thinking about regime dependency – many strategies fail because they only work in one type of market. By building an explicit regime component, James demonstrates forward-thinking and caution. Moreover, the presentation of a market-neutral (or low beta) strategy that can generate alpha is exactly what hedge funds want. Even if the strategy doesn’t have eye-popping raw returns, the fact that it’s uncorrelated alpha is valuable. James’s scientific background is evident in the way the strategy is hypothesis-driven (hypothesis: low rates benefit biotech vs pharma) and tested with data. Finally, because it’s ETF-based and relatively simple positions, he can implement it fully and show all steps within 4 weeks, including a nice visualization of how the portfolio shifts over time with regimes shaded on a chart, etc.

**Implementation Plan for Blueprint A:** (This can be enumerated as a plan/checklist style in the report)

1. **Data Gathering:** Obtain historical daily prices for XBI (biotech ETF) and XPH (or IHE – pharma ETF) from 2005 or earliest available to present. Also get macro series: 10-year Treasury yield (e.g. ^TNX or from FRED), VIX index, and perhaps BAA-AAA corporate yield spread from FRED. Put these into a time-aligned dataset (probably monthly frequency for regime decisions, while strategy trades could be monthly or quarterly).

2. **Define Regime Signal:** Create a time series that is 1 for risk-on months and 0 for risk-off. For example: risk-on if (yield\_6mo\_change \< \-0.5% AND S\&P500 200-day return \> 0\) OR (credit\_spread \< some percentile). James will need to choose and justify the rule – he can test a few and pick one that seems intuitive and effective in past cycles (ensuring not to overfit by using too many conditions).

3. **Backtesting the Strategy:** Simulate the strategy month by month: if risk-on at month start, allocate \+100% to XBI and \-100% to XPH for that month; if risk-off, go 0% (for simplicity) or opposite. Rebalance monthly. Collect returns of this long/short portfolio.

4. **Performance Evaluation:** Calculate CAGR, vol, Sharpe, maximum drawdown of strategy returns. Compare against: (a) the S\&P 500, (b) an always-long-biotech vs short-pharma strategy (to see if timing added value), and (c) each leg individually (biotech alone, pharma alone) to highlight how the long/short performs in different periods.

5. **Factor Analysis:** Regress the strategy’s returns (if monthly) on market excess return, SMB, HML, maybe momentum (UMD) factors[\[27\]](https://www.sciencedirect.com/science/article/abs/pii/S1544612318301004#:~:text=We%20start%20with%20the%20well,6). We expect beta \~0 (market-neutral by design) and maybe a positive loading on SMB or UMD if biotech outperformance coincides with those factors; the regression’s intercept would be the strategy’s alpha. If the alpha is significant and positive, that’s a great finding to report. If not, at least discuss what factors drive it.

6. **Robustness Tests:** Vary the regime criteria slightly (e.g. use 3-month rate change instead of 6-month, or include a different volatility threshold) and show that results are qualitatively similar, indicating the strategy is not overly dependent on one precise threshold. Possibly perform a **walk-forward test**: use data up to 2015 to optimize threshold, then test 2016-2025 as out-of-sample to see if it still did well in recent volatile times (this prevents using knowledge of COVID crash or 2020 boom in setting the rules).

7. **Documentation:** Present a plot of cumulative returns of the strategy vs S\&P and vs a static 50/50 biotech/pharma to visualize the alpha. Mark shaded regions of risk-on vs risk-off on the chart to show when the model was in which position – visually confirm it captures known episodes (e.g. you’d expect to see it risk-on in 2013-2014 QE era, risk-off in 2008, back on in 2009 after Fed intervention, etc.). This will tie the strategy to economic history, demonstrating understanding.

8. **Discussion of Results:** Write an analysis of how the strategy fared: e.g. “The regime-switching biotech/pharma strategy achieved an annualized return of X% with volatility Y%, Sharpe \~Z, and a low correlation to the S\&P500 (\~0.X). It significantly mitigated drawdowns (max DD \~ \-A% versus \-B% for a biotech-only approach), especially during 20xx and 20yy risk-off periods. The regression analysis shows an alpha of M% (t-stat …)[\[23\]](https://www.sciencedirect.com/science/article/abs/pii/S1544612318301004#:~:text=We%20start%20with%20the%20well,6), indicating the strategy added value beyond market and size factors.” Then note any periods it struggled (perhaps whipsaw around regime transitions, e.g. late 2018 when the Fed shifted stance quickly, etc.) and how one might handle that (maybe incorporate a bit of momentum signal to confirm before switching). Also mention real-world implementation considerations: transaction costs for switching once in a while are negligible (ETFs are liquid, monthly trade, and often one leg is financed by the other), and the short position in XPH requires ability to short ETFs (which hedge funds can do easily; if James were limited, he could use an inverse ETF as a proxy, but that’s more for retail). Since the target audience is hedge fund, shorting is fine.

### **Blueprint B: Volatility-Targeted Healthcare Momentum Strategy**

**Strategy Outline:** This blueprint focuses on **momentum-based sector rotation within healthcare**, upgraded with volatility targeting and robust validation. It draws from Strategy 1 (volatility-managed momentum) and parts of Strategy 3 (multi-factor ideas, but primarily momentum). It will demonstrate a more classic quant trend strategy, but executed with professional rigor. The strategy will allocate among a set of healthcare ETFs (e.g. {Biotech (XBI), Pharma (XPH), Medical Devices (IHI), Providers (IHF), Healthcare Tech, etc., plus maybe XLV}) based on momentum signals, while controlling risk via volatility scaling and possibly including a **risk-off safeguard** (like moving partly to cash or a low-vol asset if all health subsectors are in downtrend).

* **Rationale:** Momentum is a well-documented phenomenon – assets that have outperformed recently tend to continue outperforming in the near future. Within the healthcare sector, different industries exhibit momentum due to investor flows and sector rotation macro trends. For example, there are periods when biotech and devices are in vogue (strong momentum) while pharma lags, and vice versa. A rotational strategy can exploit these swings. However, as literature warns, sector momentum’s edge has faded[\[8\]](https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4988543#:~:text=In%20this%20article%2C%20we%20explore,effective%20tool%20for%20systematic%20investors), so the rationale for success here hinges on two things: (1) **Behavioral/cyclical flows** – investors often herd into certain healthcare themes (like gene therapy boom, or pandemic vaccine rally) causing momentum that can be tactically followed; and (2) **Risk management** – by cutting risk when volatility is high (often momentum crashes coincide with volatility spikes), the strategy can avoid the worst downsides, thus preserving the momentum premium.

* **Universe & Signals:** James will pick a reasonable set of ETFs, likely 4-5, that cover distinct slices of healthcare: e.g. XBI (biotech), IHF (healthcare providers/insurers), IHI (medical devices), XPH (pharma), maybe XLV (broad sector) or an international health ETF for diversification. Each month (or quarter), compute the total return over the past 6 or 12 months (common momentum lookback) for each ETF. Rank the ETFs by this momentum. The base signal is to overweight those with the highest momentum and underweight or zero-weight the lowest. A simple implementation: allocate 100% to the top 1 (or top 2\) momentum ETF(s), rebalancing monthly. However, to reduce churn and extreme bets, he might allocate, say, 60% to the top momentum and 40% to the second, or use an average of 3 highest minus short the lowest (but shorting multiple might add complexity; probably staying long-only is fine for this project).

* **Volatility Targeting:** After determining weights from momentum, scale the position sizes such that the expected portfolio volatility is a fixed target, e.g. 10% annualized. This means if the chosen ETF has a 20% vol, invest only half of capital in it (the rest in cash) to achieve 10% vol; if it’s lower vol, invest more. This ensures the strategy doesn’t inadvertently take on excessive risk when the winning sector is very volatile (like biotech in a frenzy) and conversely uses leverage (or full capital) when the winning sector is relatively stable (like pharma might be the top in a quiet market). The effect is a smoother equity curve and often a higher Sharpe ratio[\[9\]](https://papers.ssrn.com/sol3/Delivery.cfm/SSRN_ID4689199_code73374.pdf?abstractid=4478316#:~:text=Strategy%20papers,the%20switching%20strategy%20has), as noted in studies. James can implement this by calculating a volatility estimate for each ETF (perhaps the 1-year daily vol) and for the portfolio mix, then adjusting allocation proportionally. If not actual leverage, he can just reduce exposure (hold some cash) when needed. Since holding cash drags returns, another refinement could be to allocate unused portion to a low-risk asset (like SHY – short-term Treasury ETF) to eke some yield, but that detail might be minor given low yields.

* **Risk-Off Safeguard:** Similar to blueprint A but simpler, incorporate a rule: if the **overall healthcare sector momentum is negative** (e.g. XLV 6-month return \< 0 or the average of all ETF momenta \< 0), then reduce exposure (maybe go 50% cash or entirely shift to a defensive asset like XLV or even a bond ETF). This prevents the strategy from going long a “least bad” sector in an absolute downtrend, which is a mistake some momentum systems make (relative momentum could still pick a sector that’s losing money, just less than others). By requiring some absolute momentum or using a cash filter, he improves returns in bear markets at the expense of sometimes sitting out (which is fine). Alternatively, he could allow shorting the worst sector as an additional leg (long best, short worst); that would make it market-neutral-ish and potentially profitable in down markets too. But shorting adds complexity and risk (especially if the worst sector suddenly rebounds sharply). Given time, a long-only with cash option is safer.

* **Backtesting & Results:** James will backtest this strategy from, say, 2007 to 2025 (given ETF data availability). He will compare it to a static equal-weight of those ETFs or just XLV to see if it adds value. Key expected outcomes: The vol targeting likely yields a **higher Sharpe** than non-targeted, and the momentum rotation should yield a **higher CAGR** than static if momentum existed in this period. It’s possible that since 2010s had several rotations (biotech boom 2013-15, then crash, then device stocks did well, etc.), the strategy should capture some of that. He may find that including 2020-2021 helps a lot (biotech soared then crashed; a momentum strategy would ride up and hopefully cut before the crash if using vol or trend filters). The strategy’s turnover might be monthly, so he should subtract a small transaction cost (maybe 0.1% each trade) in the backtest to be realistic. Because ETFs are liquid, this cost is minor, but it’s good practice to include it.

* **Robustness:** There are many parameters (lookback window, number of ETFs to pick, vol target level, etc.). James should show that the strategy isn’t overly optimized: e.g., a 6-month vs 12-month momentum both work reasonably, picking top 2 vs top 1 still yields positive results, etc. If one set of parameters is much better in-sample, he should be wary and either justify (perhaps healthcare momentum works best at a certain horizon known in literature) or present that as an exploration with out-of-sample confirmation. He should also test a more recent out-of-sample (for instance, calibrate on 2007-2017, test on 2018-2025) to mimic how it might perform on unseen data. Given momentum is a known effect, it likely works similarly out-of-sample, albeit weaker. If the performance is only slightly better than benchmark, that’s okay – he can emphasize risk-adjusted metrics. Even if it underperforms in absolute return (possible if healthcare had structural uptrend that staying fully invested beat moving to cash occasionally), a higher Sharpe and lower drawdown can be sold as a plus for a hedge fund (they value consistency and lower risk).

* **Factor and Exposure Analysis:** This strategy is mostly long-only in healthcare equities, so it will have a beta to the stock market and to the healthcare sector. He should analyze what exposures it has: presumably always being in healthcare, its beta to S\&P might be \~0.8-1 on average. But perhaps because it sometimes goes to cash or switches to defensive, it might have slightly lower beta than XLV. He can compute its beta and also see if it has a tilt: does it systematically prefer higher beta sectors (likely yes, because biotech often has momentum in bull runs) meaning it might implicitly load on the momentum factor and maybe the growth factor. It could also be somewhat sector-neutral if it rotates widely, but since all are healthcare, the sector factor is common. This section is more about demonstrating he checked that the strategy isn’t unknowingly just levering the market or something. If the vol target is applied, the overall beta might be stabilized around something.

* **Why it Fits & Impresses:** This blueprint is more **classical quant** – it shows James can implement a known strategy type with improvements. It highlights his quantitative rigor: volatility targeting (which many entrants to the field wouldn’t think of) shows he studied advanced techniques. Also, by doing thorough validation (out-of-sample testing, transaction cost inclusion, factor analysis), he’s essentially mimicking the process a quant team would follow to vet a strategy. For the audience, even though momentum is plain, seeing it tailored to healthcare and executed professionally is valuable. It says James can take general quant knowledge and apply it to the healthcare domain data, producing a strategy that could potentially be part of a larger multi-sector model. James’s strength in coding will shine here – he can mention how he vectorized the backtest or how the code is organized to easily try different parameter sets (maybe he built a small framework or at least a clean script). His attention to detail in risk management and bias avoidance (like explicitly noting “we avoid look-ahead bias by using only past data at each step, and account for survivorship by using actual ETF data which inherently includes the right constituents at the time”) will further show his readiness to work in a quant environment.

**Implementation Plan for Blueprint B:**

1. **Data Prep:** Collect daily price data for chosen ETFs (XBI, XPH, IHF, IHI, XLV for example). Calculate total return index for each (adjusted close including dividends). Ensure consistent history (maybe from 2007 or 2010 onward when all ETFs exist; some like IHF started 2006).

2. **Signal Calculation:** For each month-end (or trading day if using daily signals, but monthly likely), compute 6-month and 12-month past return for each ETF (excluding the most recent month if using standard momentum definition to avoid short-term reversal, but given monthly frequency, we might ignore that nuance). Rank ETFs. Possibly smooth the signal by combining 6m and 12m or using a weighted average for stability.

3. **Allocation Rule:** Decide top N to long. For instance, long the top 2 ETFs equally (50% each) – but then apply vol scaling. To do that, estimate each ETF’s annual volatility (e.g. via 20-day or 60-day historical vol extrapolated). If both chosen ETFs have vol such that the combined portfolio vol \> target, scale down proportionally. A simpler method: target vol per position \~ 10% (so if an ETF’s vol is 20%, allocate 0.5 weight; if vol is 10%, allocate full weight). Ensure weights sum to \<= 1 (excess is cash). This can be done each month. Also, include the **cash filter**: if the max momentum among the ETFs is negative (meaning even the “best” sector had negative return past 6m), then do not allocate to risky assets at all that month (i.e. sit in cash or SHY). This prevents catching falling knives.

4. **Backtest:** Step through each month from start to end, applying the above rules, and record returns. Deduct a small transaction cost when the allocation changes (e.g. if switching from one ETF to another, assume 0.1% slippage each). Track turnover metric as well (annual turnover %) to report.

5. **Evaluation:** Compute strategy performance stats vs benchmarks: compare to XLV (the broad sector ETF buy-and-hold) and to equal-weight portfolio of all chosen ETFs rebalanced monthly (to see if momentum timing beat a naive diversification). Key metrics: CAGR, vol, Sharpe, Sortino, max drawdown, Calmar ratio (CAGR/MaxDD). Also compute **up-capture and down-capture** vs XLV (did the strategy capture a good fraction of upside in up months and avoid a lot of downside in down months? Ideally momentum will have high down-capture \< 100%). This will underscore its defensive advantage if any.

6. **In-Sample vs OOS:** If possible, split the period. For example, use 2010-2016 as an in-sample to pick parameters (like lookback 6m vs 9m, top1 vs top2, vol target 10% vs 12%, etc. – choose whatever performed best there but also reasonable). Then test 2017-2025 with those parameters fixed to see out-of-sample results. This process can be briefly explained. If out-of-sample still shows decent performance (even if lower, but still Sharpe \> XLV Sharpe), that’s a success.

7. **Visualization:** Plot the growth of $1 of the strategy vs $1 in XLV from start to finish. Indicate on the plot major events (e.g. 2008 crash, 2015 biotech bubble burst, 2020 Covid) to discuss how the strategy reacted. Perhaps a table of year-by-year returns to show consistency (some momentum years might underperform in choppy markets, e.g. 2015-2016 possibly).

8. **Analysis:** Write up findings: e.g. “The volatility-targeted momentum strategy returned X% annually vs Y% for XLV, with a Sharpe of 1.X (versus 0.Y for XLV). Notably, its maximum drawdown was only \-Z% (versus \-W% for XLV), demonstrating superior capital preservation. This is largely due to the strategy moving to cash during severe downtrends (for instance, it went to cash in late 2008, avoiding further losses, and re-entered in mid-2009) and scaling down exposure when volatility spiked (e.g. in early 2020, it reduced position size as the market became volatile). The trade-off is occasional lag in strong mean-reverting rallies (for example, in a sudden V-shaped recovery, momentum might re-enter late). Transaction costs were low given \~X% turnover annually, and even accounting for them the strategy retained strong performance.” He should also mention if there were long stretches of underperformance – momentum can underperform in range-bound markets, so identify if 2011-2012 or some period gave back a bit, to be transparent.

9. **Factor exposure check:** Likely, regressing this strategy vs Fama-French factors, we’ll see a beta \~ something to the market (less than 1 thanks to cash periods), maybe a slight tilt to momentum factor (UMD) by construction, and maybe SMB if momentum favored small-cap biotech often. He can report that no unexplained weird exposures are present beyond what we intend. The alpha vs a healthcare benchmark might or might not be significant depending on period; if momentum was weak, maybe not huge alpha. But a positive information ratio against XLV would still be good to show.

10. **Extensions:** James can mention potential improvements or variations: e.g., incorporate a fundamental factor into the selection (like avoid extremely high valuation sector even if momentum is high, to reduce crash risk – which is like adding a value filter), or expand to more sectors (though out of scope, but shows forward thinking: “this approach could be extended to rotate among all S\&P sectors, not just within healthcare, to capture broader opportunities – though here I focused on healthcare to leverage domain knowledge”).

These two blueprints (A: Regime-Switch L/S, and B: Vol-target Momentum) were chosen because they align with **James’s background** and the **target audience**:

* Blueprint A directly uses healthcare-specific knowledge (how macro environment impacts biotech vs pharma) – this leverages James’s familiarity with biotech industry cycles and shows he can derive a finance hypothesis from it. Hedge fund pods will appreciate that domain integration.

* Blueprint B demonstrates James’s **quantitative skill** in a more general sense (any quant researcher should know how to do a momentum backtest with vol targeting). It’s a chance for him to show coding proficiency, statistical thoroughness, and understanding of risk management. While not healthcare-specific in hypothesis, it still deals with healthcare assets, and he can weave in some interpretation (e.g., noticing which subsectors tended to be winners – “often the momentum strategy gravitated to medical devices in the 2010s as they had steady growth, whereas in other periods biotech dominated momentum rankings. This indicates the model effectively identifies the leadership within healthcare at any given time, something a fundamental sector portfolio manager would also aim to do.”) This ties quant results back to fundamental stories, which impresses sector specialists.

By fully developing these blueprints in the project, James will cover a lot of ground: **market-neutral alpha extraction (Blueprint A)** and **directional/tactical alpha with risk control (Blueprint B)**. Together, they showcase versatility – he can do relative value and absolute return strategies, he understands both macro regimes and pure price momentum, and he can justify both with reasoning.

## Execution Checklist and Best Practices

To ensure the project meets high standards of rigor and clarity, James should follow a structured execution plan. Below is a **checklist of key steps and best practices** that he must complete, along with how they demonstrate required competencies:

* **✅ Define Clear Hypotheses:** For each strategy, write down the investment thesis *before* seeing final results (e.g. “If interest rates fall, biotech will outperform pharma due to cheaper capital – I expect a long-biotech/short-pharma portfolio to generate positive returns in those conditions”). This will keep analysis grounded and avoid after-the-fact rationalization[\[20\]](https://bookdown.org/palomar/portfoliooptimizationbook/8.2-seven-sins.html#:~:text=8.2.3%20Sin%20). *Demonstrates:* clear investment hypothesis formulation and domain insight.

* **✅ Data Acquisition and Validation:** Gather all necessary data from reputable free sources (Yahoo Finance via yfinance for ETFs[\[21\]](https://github.com/ranaroussi/yfinance#:~:text=Image%3A%20ranaroussi), FRED for macro, Ken French library for factors). Verify data integrity: check for any missing dates, ensure dividend adjustments are handled (use total return where possible), and align time frames. No forward-looking data should be used (avoid look-ahead bias by, for example, only using data up to time *t* to make decisions at *t*). *Demonstrates:* research engineering (data handling) and avoidance of common backtest sins (look-ahead, survivorship)[\[18\]](https://bookdown.org/palomar/portfoliooptimizationbook/8.2-seven-sins.html#:~:text=%2A%20Sin%20,Asymmetric%20pattern%20and%20shorting%20cost).

* **✅ Modular Code Development:** Implement backtesting in a modular way – e.g. a function for “compute momentum signals”, a function for “apply strategy rules to get positions”, etc. Include parameters for things like lookback window or thresholds so that they can be easily changed and tested. Use version control (Git) to track changes. Possibly maintain a Jupyter notebook for iterative analysis and a separate script for final simulation runs for reproducibility. *Demonstrates:* solid software engineering practices in research – code readability, modularity, reproducibility.

* **✅ Include Transaction Costs and Constraints:** Set reasonable assumptions for trading frictions – e.g. 0.05% slippage per transaction (since ETFs are liquid) and maybe short borrow cost of \~2% annual if shorting is involved. Incorporate these into performance calculations. Also enforce realistic constraints, like no exceeding 100% capital usage (unless explicitly allowing leverage in vol targeting case, then state the leverage level used). Ensure short positions are reflected properly (e.g. borrowing costs or at least opportunity cost of short). *Demonstrates:* practical understanding of implementation issues and ensures backtest isn’t over-optimistic.

* **✅ Out-of-Sample Testing:** Divide data into a training period and a testing (hold-out) period. Use the training period to tune any strategy parameters (if needed) or at least to establish the strategy logic. Then run the strategy on the hold-out period without changing parameters. Document the performance. This simulates how the strategy might work going forward and guards against overfitting to the full history[\[19\]](https://mathinvestor.org/2022/02/backtest-overfitting-and-the-post-hoc-probability-fallacy/#:~:text=By%20backtest%20overfitting%2C%20we%20mean,sample). If the strategy performs significantly worse out-of-sample, acknowledge it and analyze why. *Demonstrates:* quantitative rigor in evaluating robustness.

* **✅ Statistical Analysis of Results:** Compute not just raw returns but also risk-adjusted metrics: Sharpe ratio, Information ratio (if comparing to a benchmark), maximum drawdown, and perhaps t-statistics for alpha. Perform regressions of strategy returns on standard factors[\[23\]](https://www.sciencedirect.com/science/article/abs/pii/S1544612318301004#:~:text=We%20start%20with%20the%20well,6) to see if alpha remains (e.g. does the momentum strategy simply load on momentum factor or truly add alpha?). Use appropriate statistical tests (t-test on mean return, maybe the **Jobson-Korkie test** to compare Sharpe ratios if advanced, or simpler, just report differences). Also check distribution of returns for any abnormal skew/kurtosis which might indicate tail risks. *Demonstrates:* finance literacy (knowing how to evaluate a strategy like a professional would).

* **✅ Sensitivity and Scenario Analysis:** Vary key assumptions to test strategy sensitivity. For example, run the momentum strategy with 3, 6, 12-month lookback to see if results are broadly similar (they don’t have to be optimal, just not completely opposite). Test the regime strategy under extreme scenarios: e.g., simulate what if interest rates had a sudden spike beyond historical range – how would strategy respond (maybe using a stress test or looking at worst historical regime shifts like 2008)? If possible, conduct a **Monte Carlo bootstrap** of returns to see confidence intervals for performance metrics (though not strictly necessary, it’s a nice touch). At minimum, illustrate how the strategies behaved in specific past volatile periods (like 2008, 2020\) to give a sense of scenario performance. *Demonstrates:* an ability to assess strategy robustness and not just trust a single backtest blindly.

* **✅ Documentation and Visualization:** Prepare clear charts and tables: equity curve plots, bar charts of annual returns, tables of performance metrics, maybe a heatmap of strategy allocation over time (to visualize how it rotated). Include a table checklist of strategy features vs. goals, e.g.:

| Goal/Feature | Addressed in Strategy? | Explanation |
| :---- | :---- | :---- |
| Uses only ETF data | Yes ✅ | Data from Yahoo Finance for all positions. |
| Avoids look-ahead bias | Yes ✅ | Signals use trailing data only, code uses past indexes. |
| Risk management (vol control, stops) | Yes ✅ | Vol targeting implemented; cash in adverse regimes. |
| Out-of-sample validation | Yes ✅ | Strategy tested on 2018–2023 unseen data with similar results. |
| Clear performance edge vs benchmark | Yes (moderate) ✅ | Sharpe improved from 0.5 (benchmark) to 0.8; max DD halved. |
| Reproducibility | Yes ✅ | Code and data references provided for replication. |

This kind of table succinctly assures the reader (and interviewer) that James checked all the boxes. *Demonstrates:* attention to detail and communication skills, making it easy for others to evaluate the project.

* **✅ Risk Discussion:** In the written report, dedicate a section to discuss potential risks and limitations. For example: model risk (if relationships change, e.g. biotech and pharma correlation might shift if, say, large pharma acquires many biotechs – then the lines blur), regulatory risk (a sudden law affecting drug pricing could hurt pharma and help biotech or vice versa unpredictably), or simply statistical risk (the strategies are tested on \~15-20 years of data – limited sample, could be luck). Acknowledge these and perhaps suggest how to monitor or mitigate them (e.g. “I would monitor the strategy with a rolling 3-year Sharpe; if it falls below zero for a period, that might indicate the edge is gone and we should reassess”). Also mention implementation considerations: slippage in real execution could be higher in a crisis, shorting ETFs might sometimes have limited availability (though unlikely for large ones), etc. *Demonstrates:* a practitioner mindset – not being blindly optimistic about backtest, but thinking of real-world execution and maintenance.

* **✅ Conclusions and Next Steps:** Conclude with what the **findings mean**: e.g. “This project shows that with a systematic approach, we can exploit certain behaviors in the healthcare sector – momentum and regime effects – to potentially generate alpha. The strategies developed achieved better risk-adjusted returns than a passive sector investment, illustrating the value of quantitative timing in healthcare. For a hedge fund context, these could be starting points for a broader strategy (they could be integrated with other sector strategies or scaled up with leverage given their risk profile). Next steps could include incorporating individual stock data for finer granularity or exploring machine learning techniques on a wider set of features (fundamentals, sentiment) to see if we can improve predictions – though careful to avoid overfitting. The project also highlights the importance of rigorous validation and risk management, which I will carry forward in any quant research role.” *Demonstrates:* ability to synthesize results and envision how to extend or apply them, showing enthusiasm and foresight.

By following this checklist, James will produce a comprehensive project that not only has two well-crafted strategy case studies but also convinces readers that he approaches quantitative finance problems methodically and thoughtfully. The end result will be an **executive-style report, a set of reproducible code/notebooks, and polished visuals**, all reflecting a level of professionalism comparable to what’s expected in industry research reports.

---

**Conclusion:** Through the upgraded project defined above, James will showcase a rare combination of skills. He will extract quantifiable signals from his understanding of the healthcare sector and validate them with data-driven methods. The deliverables – including an executive summary of findings, a literature review section situating his strategies in context, detailed strategy analysis with supporting tables/figures, and a checklist of robustness measures taken – will demonstrate that James can formulate clear investment hypotheses, implement disciplined backtests, and critically evaluate results **like a practitioner**. By emphasizing risk-adjusted performance, factor exposures, and the impact of market regimes, he addresses exactly the concerns a hedge fund PM would raise. Furthermore, by organizing his research process in a transparent, reproducible manner (good coding practices, careful documentation), he signals that he’s ready to contribute in a professional quantitative research environment.

Ultimately, this project – focusing on **healthcare ETF strategies** – not only fills the gaps in James’s resume (by providing tangible finance experience and accomplishments), but also leverages his existing strengths (scientific research mindset and domain knowledge). It will serve as a bridge demonstrating how he can add value in a healthcare-focused hedge fund pod: by systematically turning healthcare insights into profitable, well-controlled trading strategies backed by evidence.

**Sources:**

* James Lee – CV and Skills (Computational biology, programming, ML experience)[\[1\]](file://file-3p3YJtzbTrCpuyR3KaG14n#:~:text=Research%20Assistant%20at%20Sanjana%20Lab,Present)[\[4\]](file://file-3p3YJtzbTrCpuyR3KaG14n#:~:text=Computational%20Biology%3A%20Python%2C%20R%2C%20Bash%2C,MAGeCK%2FSCEPTRE%2FPertPy)

* Sector Momentum Literature (diminishing alpha, improvements needed)[\[8\]](https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4988543#:~:text=In%20this%20article%2C%20we%20explore,effective%20tool%20for%20systematic%20investors)[\[9\]](https://papers.ssrn.com/sol3/Delivery.cfm/SSRN_ID4689199_code73374.pdf?abstractid=4478316#:~:text=Strategy%20papers,the%20switching%20strategy%20has)

* Pairs Trading and ETF Mean Reversion studies[\[11\]](https://papers.ssrn.com/sol3/papers.cfm?abstract_id=2816288#:~:text=Is%20Daily%20Pairs%20Trading%20of,clear%20if%20it%20still)

* Healthcare Sector Analysis (subsector differences: growth vs stability, funding cycles)[\[12\]](https://www.home.saxo/content/articles/equities/healthcare-rotation--a-timely-diversification-opportunity-for-tech-heavy-portfolios-26112025#:~:text=Investor%20takeaway%3A%20Healthcare%20is%20diversified,risks%20alongside%20its%20potential%20benefits)[\[13\]](https://www.home.saxo/content/articles/equities/healthcare-rotation--a-timely-diversification-opportunity-for-tech-heavy-portfolios-26112025#:~:text=Image%3A%2026_CHCA_Heanthcare%20performance%20gfc)

* Biotechnology vs Pharma Risk and Returns (R\&D intensity, risk exposure, performance)[\[14\]](https://www.nber.org/papers/w13604#:~:text=The%20biotechnology%20industry%20has%20been,was%20only%20about%203%20percent)[\[15\]](https://www.nber.org/papers/w13604#:~:text=biotechnology%20firms%20to%20estimate%20several,be%20underestimated%20when%20a%20single)[\[16\]](https://link.springer.com/article/10.1007/s10754-020-09291-1#:~:text=of%20capital,the%20pharmaceutical%20supply%20chain%20are)

* Data Sources (Yahoo Finance via yfinance, Alpha Vantage API)[\[21\]](https://github.com/ranaroussi/yfinance#:~:text=Image%3A%20ranaroussi)[\[22\]](https://www.tha.de/en/library/Alpha-Vantage-API.html#:~:text=Alpha%20Vantage%20API%20,and%20500%20daily%20calls%20limit) and Fama-French factor availability[\[23\]](https://www.sciencedirect.com/science/article/abs/pii/S1544612318301004#:~:text=We%20start%20with%20the%20well,6)

* Backtesting Pitfalls and Best Practices (overfitting, biases, costs)[\[19\]](https://mathinvestor.org/2022/02/backtest-overfitting-and-the-post-hoc-probability-fallacy/#:~:text=By%20backtest%20overfitting%2C%20we%20mean,sample)[\[18\]](https://bookdown.org/palomar/portfoliooptimizationbook/8.2-seven-sins.html#:~:text=%2A%20Sin%20,Asymmetric%20pattern%20and%20shorting%20cost)

---

[\[1\]](file://file-3p3YJtzbTrCpuyR3KaG14n#:~:text=Research%20Assistant%20at%20Sanjana%20Lab,Present) [\[2\]](file://file-3p3YJtzbTrCpuyR3KaG14n#:~:text=Developed%20single,high%20sensitivity%20in%20one%20experiment) [\[3\]](file://file-3p3YJtzbTrCpuyR3KaG14n#:~:text=Computational%20Biology%3A%20Python%2C%20R%2C%20Bash%2C,MAGeCK%2FSCEPTRE%2FPertPy) [\[4\]](file://file-3p3YJtzbTrCpuyR3KaG14n#:~:text=Computational%20Biology%3A%20Python%2C%20R%2C%20Bash%2C,MAGeCK%2FSCEPTRE%2FPertPy) [\[5\]](file://file-3p3YJtzbTrCpuyR3KaG14n#:~:text=Peer) [\[6\]](file://file-3p3YJtzbTrCpuyR3KaG14n#:~:text=Lee%2C%20H.%20J.,Cancers) [\[7\]](file://file-3p3YJtzbTrCpuyR3KaG14n#:~:text=scPerturb,repurposing%20prediction%20for%20bench%20validation) CV\_industry\_James\_Lee.docx

[file://file-3p3YJtzbTrCpuyR3KaG14n](file://file-3p3YJtzbTrCpuyR3KaG14n)

[\[8\]](https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4988543#:~:text=In%20this%20article%2C%20we%20explore,effective%20tool%20for%20systematic%20investors) How to Improve ETF Sector Momentum \* by Soňa Beluská, Radovan Vojtko :: SSRN

[https://papers.ssrn.com/sol3/papers.cfm?abstract\_id=4988543](https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4988543)

[\[9\]](https://papers.ssrn.com/sol3/Delivery.cfm/SSRN_ID4689199_code73374.pdf?abstractid=4478316#:~:text=Strategy%20papers,the%20switching%20strategy%20has) \[PDF\] Market Volatility, Momentum, and Reversal: A Switching Strategy

[https://papers.ssrn.com/sol3/Delivery.cfm/SSRN\_ID4689199\_code73374.pdf?abstractid=4478316](https://papers.ssrn.com/sol3/Delivery.cfm/SSRN_ID4689199_code73374.pdf?abstractid=4478316)

[\[10\]](http://www.na-businesspress.com/JAF/JAF21-1/3_ColeFinal.pdf#:~:text=,the%20testing%20of%20these) \[PDF\] Time Series Momentum in Sector Based ETFs

[http://www.na-businesspress.com/JAF/JAF21-1/3\_ColeFinal.pdf](http://www.na-businesspress.com/JAF/JAF21-1/3_ColeFinal.pdf)

[\[11\]](https://papers.ssrn.com/sol3/papers.cfm?abstract_id=2816288#:~:text=Is%20Daily%20Pairs%20Trading%20of,clear%20if%20it%20still) Is Daily Pairs Trading of ETF-Stocks Profitable? \- SSRN

[https://papers.ssrn.com/sol3/papers.cfm?abstract\_id=2816288](https://papers.ssrn.com/sol3/papers.cfm?abstract_id=2816288)

[\[12\]](https://www.home.saxo/content/articles/equities/healthcare-rotation--a-timely-diversification-opportunity-for-tech-heavy-portfolios-26112025#:~:text=Investor%20takeaway%3A%20Healthcare%20is%20diversified,risks%20alongside%20its%20potential%20benefits) [\[13\]](https://www.home.saxo/content/articles/equities/healthcare-rotation--a-timely-diversification-opportunity-for-tech-heavy-portfolios-26112025#:~:text=Image%3A%2026_CHCA_Heanthcare%20performance%20gfc) Healthcare rotation A timely diversification opportunity for tech-heavy portfolios | Saxo

[https://www.home.saxo/content/articles/equities/healthcare-rotation--a-timely-diversification-opportunity-for-tech-heavy-portfolios-26112025](https://www.home.saxo/content/articles/equities/healthcare-rotation--a-timely-diversification-opportunity-for-tech-heavy-portfolios-26112025)

[\[14\]](https://www.nber.org/papers/w13604#:~:text=The%20biotechnology%20industry%20has%20been,was%20only%20about%203%20percent) [\[15\]](https://www.nber.org/papers/w13604#:~:text=biotechnology%20firms%20to%20estimate%20several,be%20underestimated%20when%20a%20single) [\[25\]](https://www.nber.org/papers/w13604#:~:text=the%20CAPM%20does%20not%20reflect,factor%20model) [\[26\]](https://www.nber.org/papers/w13604#:~:text=In%20the%20current%20study%20we,prices%20and%20returns%2C%20and%20R%26D) Financial Risk in the Biotechnology Industry | NBER

[https://www.nber.org/papers/w13604](https://www.nber.org/papers/w13604)

[\[16\]](https://link.springer.com/article/10.1007/s10754-020-09291-1#:~:text=of%20capital,the%20pharmaceutical%20supply%20chain%20are) Do companies in the pharmaceutical supply chain earn excess returns? | International Journal of Health Economics and Management

[https://link.springer.com/article/10.1007/s10754-020-09291-1](https://link.springer.com/article/10.1007/s10754-020-09291-1)

[\[17\]](https://pubmed.ncbi.nlm.nih.gov/19799470/#:~:text=,suffered%20more%20negative%20stock%20returns) Financial risk of the biotech industry versus the pharmaceutical ...

[https://pubmed.ncbi.nlm.nih.gov/19799470/](https://pubmed.ncbi.nlm.nih.gov/19799470/)

[\[18\]](https://bookdown.org/palomar/portfoliooptimizationbook/8.2-seven-sins.html#:~:text=%2A%20Sin%20,Asymmetric%20pattern%20and%20shorting%20cost) [\[20\]](https://bookdown.org/palomar/portfoliooptimizationbook/8.2-seven-sins.html#:~:text=8.2.3%20Sin%20) 8.2 The Seven Sins of Quantitative Investing | Portfolio Optimization

[https://bookdown.org/palomar/portfoliooptimizationbook/8.2-seven-sins.html](https://bookdown.org/palomar/portfoliooptimizationbook/8.2-seven-sins.html)

[\[19\]](https://mathinvestor.org/2022/02/backtest-overfitting-and-the-post-hoc-probability-fallacy/#:~:text=By%20backtest%20overfitting%2C%20we%20mean,sample) Backtest overfitting and the post-hoc probability fallacy « Mathematical Investor

[https://mathinvestor.org/2022/02/backtest-overfitting-and-the-post-hoc-probability-fallacy/](https://mathinvestor.org/2022/02/backtest-overfitting-and-the-post-hoc-probability-fallacy/)

[\[21\]](https://github.com/ranaroussi/yfinance#:~:text=Image%3A%20ranaroussi) GitHub \- ranaroussi/yfinance: Download market data from Yahoo\! Finance's API

[https://github.com/ranaroussi/yfinance](https://github.com/ranaroussi/yfinance)

[\[22\]](https://www.tha.de/en/library/Alpha-Vantage-API.html#:~:text=Alpha%20Vantage%20API%20,and%20500%20daily%20calls%20limit) Alpha Vantage API \- Technische Hochschule Augsburg

[https://www.tha.de/en/library/Alpha-Vantage-API.html](https://www.tha.de/en/library/Alpha-Vantage-API.html)

[\[23\]](https://www.sciencedirect.com/science/article/abs/pii/S1544612318301004#:~:text=We%20start%20with%20the%20well,6) [\[27\]](https://www.sciencedirect.com/science/article/abs/pii/S1544612318301004#:~:text=We%20start%20with%20the%20well,6) Risk premium contributions of the Fama and French mimicking factors \- ScienceDirect

[https://www.sciencedirect.com/science/article/abs/pii/S1544612318301004](https://www.sciencedirect.com/science/article/abs/pii/S1544612318301004)

[\[24\]](https://fred.stlouisfed.org/docs/api/fred/#:~:text=St,category%2C%20series%2C%20and%20other) St. Louis Fed Web Services: FRED® API

[https://fred.stlouisfed.org/docs/api/fred/](https://fred.stlouisfed.org/docs/api/fred/)

# Action Plan

\[Contains Unverified Content\]

## **Answer**

I will treat this as your **project operating manual** for the next 4 weeks and explain each finance concept as we go.

I am going to do three things:

1. Translate the project into **two concrete strategies** and a small set of workstreams.

2. Lay out a **4 week, step by step plan**, with explanations of all the finance terms.

3. Summarize the **expected deliverables** so you know what “done” looks like.

---

### **1\. Big picture: what you are actually building**

#### **1.1 Strategies we focus on**

**Primary strategy – “Regime switching biotech vs pharma” \[Inference\]**

* Universe: one biotech ETF (for example XBI) and one pharma ETF (for example XPH).

* “ETF”: tradable fund that holds a basket of stocks and trades like a single stock.

* Idea:

  * When the macro environment looks **risk friendly** (low or falling interest rates, calm equity markets) you expect **biotech to outperform pharma**, because funding is cheap and investors tolerate R\&D risk.

  * When the environment is **risk averse** (rising rates, high volatility), you expect **pharma to do better**, because earnings are more stable and investors hide in defensives.

* Implementation:

  * In “risk on” regimes: **go long biotech, short pharma**.

    * “Go long” means you own the ETF and profit if its price goes up.

    * “Go short” means you borrow the ETF, sell it now, and profit if its price goes down. In a **long short** portfolio you are long one asset and short another at the same time.

  * In “risk off” regimes: either stand aside (flat) or favor pharma.

This is effectively a **sector relative value** strategy inside healthcare, designed to show that you can turn your biotech intuition into a tradable rule.

**Secondary strategy – “Volatility targeted healthcare momentum rotation” \[Inference\]**

* Universe: multiple healthcare ETFs, for example biotech, pharma, devices, providers, and broad healthcare.

* “Momentum”: the tendency for assets that have done well in the recent past to keep doing well over the short to medium term. You usually measure it as past 6 to 12 month return.

* Idea:

  * At each month, rank ETFs by recent performance.

  * Allocate more capital to the **strongest recent performers**.

* But with a twist: **volatility targeting**.

  * “Volatility” is the variability of returns, typically measured as the standard deviation of returns.

  * High volatility means returns jump around a lot; low volatility means they are smoother.

  * “Volatility targeting” means you scale your position sizes so that the portfolio has an approximately stable volatility over time. If your chosen ETF is very volatile, you shrink the position. If it is calm, you can safely hold more. This aims to stabilize risk and often improves **risk adjusted returns**.

  * “Risk adjusted return” is return per unit of risk, not raw return. A common metric is the **Sharpe ratio**, defined as excess return (over a risk free rate) divided by the volatility of returns. A higher Sharpe ratio means better return per unit of risk.([Wikipedia](https://en.wikipedia.org/wiki/Sharpe_ratio?utm_source=chatgpt.com))

This strategy is there to show you understand bread and butter quant tools: momentum signals, risk control, and portfolio construction.

If time gets tight, you prioritize the **regime L S strategy**, and treat the momentum strategy as “nice to have, but secondary” \[Inference\].

---

### **2\. Global workstreams with intuitive explanations**

To keep sanity, everything fits into five workstreams.

#### **WS1 – Infrastructure and data pipeline**

* Repo layout, Python environment, config files.

* Data download functions for ETF prices and macro variables.

* Basic exploratory plots and sanity checks.

Why: this proves you can build a reusable **research pipeline**, not one giant notebook.

#### **WS2 – Primary strategy: regime switching biotech vs pharma**

* Turn your intuition about “funding cycles” and “risk appetite” into **explicit rules**.

* Build a **signal function** that labels each month as “risk on” or “risk off” based on macro data.

* Generate **portfolio weights** for long/short positions per regime, run a backtest, and compute performance metrics.

#### **WS3 – Secondary strategy: momentum rotation with volatility target**

* Build momentum and volatility features for several healthcare ETFs.

* Decide which ETFs to overweight based on momentum and then scale positions using vol targeting so that portfolio risk is roughly controlled.

#### **WS4 – Risk, factor, and robustness analysis**

You will see a few finance words here:

* **CAGR (compound annual growth rate)**: the constant yearly growth rate that would transform starting capital into ending capital, assuming compounding. It is the standard way of summarizing average annual return over multiple years.([Investopedia](https://www.investopedia.com/terms/c/cagr.asp?utm_source=chatgpt.com))

* **Maximum drawdown**: the worst loss from a peak to the next trough in the equity curve, expressed as a percentage. It tells you “how bad did it get at the worst point”.([Investopedia](https://www.investopedia.com/terms/m/maximum-drawdown-mdd.asp?utm_source=chatgpt.com))

* **Alpha and beta**:

  * Beta measures how sensitive your strategy is to market moves. Beta of 1 means the strategy tends to move 1 percent when the market moves 1 percent.([Wikipedia](https://en.wikipedia.org/wiki/Beta_%28finance%29?utm_source=chatgpt.com))

  * Alpha is the part of return not explained by beta and a benchmark, often interpreted as “skill” or “excess return beyond market risk”.([Investopedia](https://www.investopedia.com/articles/investing/092115/alpha-and-beta-beginners.asp?utm_source=chatgpt.com))

* **Factor regression**:

  * You run a linear regression where your strategy returns are the dependent variable and standard factor returns (market, size, value, etc.) are independent variables.

  * The intercept is alpha, coefficients on factors are betas. This shows what risks you are actually taking.

In this workstream you compute:

* Basic metrics: CAGR, volatility, Sharpe ratio, max drawdown.

* Factor regressions to see if there is true alpha or if you just loaded on market or standard factors.

* Train vs test splits to check out of sample behavior.

#### **WS5 – Documentation, report, and interview material**

* Long form research style write up.

* Clean notebooks and plots.

* 1 page summary and a small “talk track” for interviews.

You are already good at writing scientific reports and building pipelines; this repurposes that skill into finance.

---

### **3\. Four week step by step plan, explained**

I will keep this concrete: for each week I specify goals, tasks, and why each is done.

---

#### **Week 1 – Repo, data, and precise strategy definitions**

**Goal:** infrastructure online, data flowing, strategy rules fixed on paper. No performance chasing yet.

##### **1.1 Set up repo and environment (WS1)**

Tasks:

Create folder structure, for example:

 /data\_raw        (raw CSVs from APIs)

/data\_processed  (cleaned, aligned time series)

/src

  /data          (download and clean functions)

  /signals       (regime labels, momentum, etc.)

  /portfolio     (position sizing, vol targeting)

  /backtest      (engine)

  /analysis      (risk metrics, factor regressions)

  /plots         (plotting helpers)

/notebooks       (EDA and final analysis)

/config          (YAML or JSON for parameters)

/tests           (unit tests)

README.md

*   
* Set up `requirements.txt` or `pyproject.toml` with:

  * `pandas`, `numpy` for time series.

  * `yfinance` or `alpha_vantage` to fetch ETF prices.

  * `statsmodels` for regressions.

  * `matplotlib` for plots.

Why: this mirrors research engineering in quant shops and makes later Codex prompts trivial (for example, “generate backtest engine in `src/backtest/engine.py`”).

##### **1.2 Data loaders (WS1)**

Tasks:

* `src/data/etf_loader.py`

  * Function `get_etf_prices(tickers, start, end)` that:

    * Calls `yfinance` or similar.

    * Returns a DataFrame of adjusted close prices.

    * Stores raw CSVs in `/data_raw` to avoid repeated downloads.

* `src/data/macro_loader.py`

  * Functions to download macro series:

    * 10 year Treasury yield.

    * VIX index.

    * Possibly a credit spread proxy.

  * Resample to monthly if you intend to make regime decisions monthly.

Explain:

* **Adjusted close** means the price series corrected for dividends and splits, so returns reflect total gain.

* You want everything on a consistent timeline, so you resample to a common frequency (likely daily for prices, monthly for macro and factor data).

##### **1.3 Specify primary strategy rules (WS2)**

Here you nail down the logic mathematically and in plain language.

Define:

* Biotech ETF, for example XBI.

* Pharma ETF, for example XPH or IHE.

* Monthly schedule: at each month end you compute macro features and decide next month’s position.

**Regime variables:**

* `delta_rate_6m`: change in 10 year yield over last 6 months.

* `spy_trend`: return of SPY over last 6 months or whether price is above its 200 day moving average.

* `vix_level`: average VIX over last month.

You then create a rule such as \[Speculation\]:

* Risk on if:

  * `delta_rate_6m < -0.5 percent` (rates have fallen, funding cheaper),

  * AND `spy_trend > 0` (equity market up),

  * AND `vix_level < threshold` (volatility moderate).

* Else risk off.

You need to pick actual thresholds later, but fix the structure now.

**Portfolio rule:**

* In risk on: long 1 dollar of XBI, short 1 dollar of XPH.

* In risk off: either flat (no positions) or long 1 dollar of XPH only.

This is a **long short** portfolio, often near market neutral:

* If long and short amounts are similar, exposure to broad market cancels partly, so you are mainly betting on biotech outperforming pharma, not on the whole market going up.

##### **1.4 Specify momentum rotation rules (WS3)**

Define ETF universe:

* For example: XBI (biotech), XPH (pharma), IHI (devices), IHF (providers), XLV (broad).

Define momentum:

* For each ETF, compute **trailing 6 month total return** up to last month end.

  * “Total return” includes price change plus dividends.

Define volatility:

* For each ETF, compute **realized volatility** from daily returns over last 60 trading days.

Allocation rule \[Speculation\]:

* Each month:

  * Rank ETFs by momentum.

  * Select top K (for example K 2).

  * Assign target **risk weight** inversely proportional to volatility.

    * Example: if ETF A has vol 20 percent per year and ETF B has 10 percent, give B double the capital share as A, to equalize risk.

* If all ETFs have negative momentum, you either:

  * Hold cash.

  * Or hold a defensive ETF such as XLV only.

This is the place where you encode “chase winners, but do not let risk explode”.

##### **1.5 Quick exploratory data analysis (WS1/WS2/WS3)**

Simple notebook tasks:

* Plot price history of each ETF.

* Plot the ratio XBI / XPH over time to see when biotech outperformed pharma.

* Plot 10 year yield vs the XBI minus XPH return to eyeball whether periods of falling rates match biotech outperformance.

Purpose: sanity check that your hypotheses are not completely contrary to history.

**End of week 1 target:**

* Code: working data loaders, basic EDA notebook.

* Writing: strategy specs for primary and secondary strategy in a markdown file.

If this slips, you should drop any thoughts of a third strategy to protect depth \[Inference\].

---

#### **Week 2 – Build backtest engine and get primary strategy running**

**Goal:** correct backtester plus a first pass of the regime long short strategy.

##### **2.1 Backtest engine (WS1)**

A **backtest** simulates how a strategy would have performed if you had traded it in the past, using only information that was available at each point in time.

Engine responsibilities:

* Input:

  * Price time series for all ETFs.

  * Time series of desired portfolio weights (for every asset at each decision date).

  * Transaction cost assumptions.

* Output:

  * Portfolio daily returns.

  * Equity curve (growth of 1 dollar over time).

  * Turnover.

Key concepts:

* **Turnover**: how much you trade as a fraction of portfolio size. If your weights change a lot from month to month, turnover is high. High turnover implies more trading costs.

* **Transaction costs**: you can model these simply as a **proportional cost** per trade, for example 0.1 percent per notional traded. Real costs are spread plus commissions; you approximate them.

Implement as:

* `src/backtest/engine.py` with functions like `run_backtest(prices, weights, costs)` returning a DataFrame of results.

* Include support for:

  * Long only portfolios (weights between 0 and 1 and sum up to 1).

  * Long short portfolios (weights can be negative, total not necessarily 1).

  * A cash asset (implicit when sum of weights is less than 1).

Unit tests:

* Create synthetic price series where you know the answer to confirm engine math is correct.

##### **2.2 Regime classification and signal generation (WS2)**

Code:

* `src/signals/regime.py`:

  * Functions to compute rolling features from macro data and generate a monthly regime label (`1 risk_on`, `0 risk_off`).

* `src/signals/ls_biotech_pharma.py`:

  * Map each monthly regime label to portfolio weights:

    * Risk on: weight XBI 1.0, XPH 1.0 (short).

    * Risk off: weights 0, 0 (flat) or XBI 0, XPH plus something.

Combine:

* Align monthly regime weights with daily prices by forward filling weights within each month.

* Feed to backtest engine.

##### **2.3 First evaluation of primary strategy (WS4)**

Compute basic performance metrics:

* **CAGR**: compute how 1 dollar grows over the backtest, then infer the equivalent constant annual growth rate.([Investopedia](https://www.investopedia.com/terms/c/cagr.asp?utm_source=chatgpt.com))

* **Volatility**: annualized standard deviation of monthly or daily returns.

* **Sharpe ratio**: (average portfolio return minus risk free rate) divided by volatility. This says how much extra return you earned per unit of risk taken.([Wikipedia](https://en.wikipedia.org/wiki/Sharpe_ratio?utm_source=chatgpt.com))

* **Maximum drawdown**: worst peak to trough loss in the equity curve.([Investopedia](https://www.investopedia.com/terms/m/maximum-drawdown-mdd.asp?utm_source=chatgpt.com))

Compare:

* Against static long XBI short XPH with constant weights.

* Against long only XLV buy and hold.

The point is not to get spectacular numbers yet, but to:

* Confirm the backtest logic works.

* See whether the regime filter does anything at all compared to always being long/short.

**End of week 2 target:**

* Backtest engine is reliable.

* Regime strategy runs end to end with basic metrics.

* You can already plot an equity curve and drawdowns.

If the engine is flaky, all effort goes to fixing it before introducing more strategy complexity \[Inference\].

---

#### **Week 3 – Implement momentum rotation and deepen analytics**

**Goal:** secondary strategy running plus risk and factor analysis for both strategies.

##### **3.1 Momentum and volatility modules (WS3)**

Code:

* `src/signals/momentum.py`:

  * Function to compute trailing N month returns for each ETF on a monthly grid.

* `src/portfolio/vol_target.py`:

  * Function that takes desired **risk weights** and vol estimates, and translates them into capital weights that respect a maximum leverage.

    * “Leverage” here means gross exposure higher than your capital. For this project, you can restrict to no leverage, so target weights sum to at most 1\.

* `src/signals/healthcare_rotation.py`:

  * For each month:

    * Compute momentum scores.

    * Select top K ETFs.

    * Use vol targeting to compute weights.

    * Apply cash rule when all momentum is negative.

Feed these weights and ETF prices into the backtest engine.

##### **3.2 Risk and factor analysis (WS4)**

Now you build the machinery to convince an interviewer you understand **what risks you are taking**.

Steps:

1. **Factor data**

   * Download Fama French factor data (market, size, value, maybe momentum) from the French data library, at monthly frequency.

   * Compute **excess returns**: strategy return minus risk free rate (T bill).

2. **Factor regression**

   * For each strategy, regress monthly excess returns on factors:

     * Example: `strategy_excess = alpha + beta_mkt * MKT + beta_smb * SMB + beta_hml * HML + error`.

   * Interpret:

     * `beta_mkt` tells how sensitive strategy is to overall market.

     * `beta_smb` tells if strategy behaves like small cap vs large cap.

     * `alpha` is the average excess return after accounting for these exposures.([Investopedia](https://www.investopedia.com/ask/answers/102714/whats-difference-between-alpha-and-beta.asp?utm_source=chatgpt.com))

3. **Train vs test split**

   * Choose a split year, for example 2016:

     * 2006 2015 as “design period”,

     * 2016 onward as “evaluation period”.

   * Recompute metrics separately in each period.

   * This tests whether the strategy only “works” in one specific slice of history (classic overfitting risk).

4. **Risk metrics beyond Sharpe**

   * **Sortino ratio**: like Sharpe but only penalizes downside volatility. This is optional but nice.

   * **Calmar ratio**: CAGR divided by maximum drawdown. This tells you return per unit of worst loss.

   * **Up capture / down capture**:

     * Up capture: average return in months when benchmark is up, divided by benchmark’s return.

     * Down capture: same in down months.

     * A strategy that captures 80 percent of upside and only 50 percent of downside is attractive.

You do not need perfect statistical rigor, but you must show you thought about **sample size, noise, and overfitting**.

##### **3.3 Code cleanup and tests (WS1)**

* Refactor duplicated code between strategies.

* Ensure there are minimal tests that fail loudly if you break core behavior later.

**End of week 3 target:**

* Momentum rotation strategy backtested with metrics.

* Factor regression results for both strategies.

* Basic robustness split between early and recent periods.

If results are mediocre, that is fine. The point is to be honest and explain why, not to torture the data until Sharpe looks pretty \[Inference\].

---

#### **Week 4 – Robustness, storytelling, and polishing**

**Goal:** turn code results into a coherent, critical research package.

##### **4.1 Robustness and sensitivity (WS4)**

You test how fragile the strategies are to reasonable parameter changes.

Examples:

* For regime strategy:

  * Try 3 vs 6 vs 9 month rate change in the regime rule.

  * Slightly adjust VIX threshold.

  * Compare performance metrics in a table.

* For momentum rotation:

  * Try 6 vs 12 month momentum.

  * Top 1 vs top 2 ETFs.

  * Target volatility 8 vs 10 vs 12 percent (if you use a numerical target).

What you want to see:

* If performance collapses when you nudge parameters, the strategy is probably overfit.

* If behavior is broadly similar across a reasonable range, you can argue it is more robust.

Also:

* Do **scenario analysis**:

  * Slice time into major episodes:

    * Global financial crisis, biotech bubble, Covid crash, 2022 rate shock.

  * For each episode, plot strategy vs XLV vs SPY.

  * Describe behavior qualitatively: did the regime model switch out of biotech during stress? Did momentum rotation reduce drawdowns?

##### **4.2 Report and communication (WS5)**

Write a **10 to 15 page report** (can be in Jupyter or LaTeX or just markdown) with:

1. **Introduction**

   * Why healthcare ETFs.

   * Why these two strategies.

2. **Data and universe**

   * ETF list, macro variables, factor data.

   * How you cleaned and aligned data.

3. **Methodology**

   * Exact definitions of signals and rules, with formulas.

   * Backtest assumptions: frequency, transaction costs, no look ahead.

4. **Results**

   * Performance metrics and plots for both strategies.

   * Comparison vs XLV and SPY.

5. **Risk and factor analysis**

   * Factor regression results with alpha and beta interpretations.

   * Discussion of what risks the strategies are actually taking.

6. **Robustness**

   * Sensitivity tables.

   * Episode analysis.

7. **Limitations and caveats**

   * Limited sample size.

   * ETF only, no single stock detail.

   * Assumptions on shorting and costs.

8. **Conclusion and potential extensions**

Also create:

* A **1 page “PM summary”** with:

  * Strategy snapshots, core metrics, main pros cons.

* A short **interview script**:

  * 2 to 3 paragraphs walking through primary strategy, data, results, and what you learned.

**End of week 4 target:**

* Stable code and data.

* Final report and summary material.

* You can explain, without slides, why the strategy might or might not be useful to a real PM.

If time is short, you cut back on extra bells and whistles (third strategies, fancy ML) and preserve: correct backtest, risk analysis, and honest discussion \[Inference\].

---

### **4\. What this sets you up for next**

Once you are comfortable with this plan, we can transform many bullets into **large Codex prompts**, for example:

* “Create `src/backtest/engine.py` with functions A, B, C given this specification.”

* “Write tests in `tests/test_engine.py` for scenarios X, Y, Z.”

* “Generate a notebook `notebooks/01_eda.ipynb` that loads ETFs and produces plots P, Q, R.”

You will then only need to glue the pieces and interpret results.

---

## **Citations**

* Your CV confirms Python, R, Bash, SQL, AWS, HPC, Git, Nextflow, Snakemake, and ML libraries, plus experience building bioinformatics pipelines and tools, which supports the assumption that you can handle the proposed repo, data, and testing setup \[Verified\].

* Definitions:

  * Sharpe ratio and risk adjusted return: additional return per unit of volatility relative to a risk free asset \[Verified\]. ([Wikipedia](https://en.wikipedia.org/wiki/Sharpe_ratio?utm_source=chatgpt.com))

  * CAGR as a constant annualized growth rate smoothing volatility over time \[Verified\]. ([Investopedia](https://www.investopedia.com/terms/c/cagr.asp?utm_source=chatgpt.com))

  * Maximum drawdown as the worst peak to trough decline in portfolio value \[Verified\]. ([Investopedia](https://www.investopedia.com/terms/m/maximum-drawdown-mdd.asp?utm_source=chatgpt.com))

  * Alpha and beta: alpha is excess return after adjusting for risk factors, beta is sensitivity of returns to a benchmark \[Verified\]. ([Investopedia](https://www.investopedia.com/ask/answers/102714/whats-difference-between-alpha-and-beta.asp?utm_source=chatgpt.com))

All strategy designs, weekly timelines, and prioritization choices are logical constructions from your goals and constraints, so they are \[Inference\] or \[Speculation\], not empirically validated.

---

## **Claim Check (with tags)**

* You can build and backtest two ETF based strategies plus risk analysis in 4 weeks if you avoid scope creep and reuse code across strategies \[Speculation\].

* The regime switching biotech vs pharma long short strategy is the best primary choice to showcase healthcare specific insight and quant reasoning for pods \[Inference\].

* The volatility targeted healthcare momentum rotation is a reasonable secondary strategy that highlights generic quant skills like signal design and risk control \[Inference\].

* Your existing computational biology and pipeline experience is sufficient to implement the repo structure, data handling, and testing described here \[Verified\].

* Prioritizing backtest correctness, bias control, and honest robustness work over “perfect Sharpe” is more valuable to practitioners than squeezing extra in sample performance \[Inference\].

---

## **Gaps & Next Steps**

**Gaps**

* The exact choice of ETFs and data start dates is not yet checked; some ETFs might have short histories that limit backtest length \[Unverified\].

* The precise thresholds for regime definitions and momentum lookbacks are not optimized; they are placeholders that you will need to test empirically \[Speculation\].

* Transaction cost and short borrow assumptions are simplified; realistic costs could reduce apparent alpha, especially for higher turnover strategies \[Inference\].

* No actual regression or backtest has been run yet, so there is no evidence that these specific implementations produce attractive performance \[Unverified\].

**Next steps for you**

1. Decide whether you accept this **two strategy scope** as is. If you already know you only want one strategy, we can deepen its plan further.

2. Run a tiny exploratory script now: pull daily prices for your candidate ETFs and confirm you have at least 15 years of history for both primary strategy ETFs.

3. Once you are comfortable with this action plan, ask me for the **Codex mega prompts**. I will then turn the most important bullets into detailed prompts you can copy paste to generate code modules, notebooks, and tests.

If anything in the plan feels opaque, tell me which part and I can zoom in and re explain that piece more slowly.

